<article article-type="review-article" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="iso-abbrev">J Clin Transl Hepatol</journal-id><journal-id journal-id-type="pmc-domain-id">2787</journal-id><journal-id journal-id-type="pmc-domain">jcth</journal-id><journal-id journal-id-type="publisher-id">JCTH</journal-id><journal-title-group><journal-title>Journal of Clinical and Translational Hepatology</journal-title></journal-title-group><issn pub-type="ppub">2225-0719</issn><issn pub-type="epub">2310-8819</issn><publisher><publisher-name>Xia &amp; He Publishing Inc. (USA)</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12872391</article-id><article-id pub-id-type="pmcid-ver">PMC12872391.1</article-id><article-id pub-id-type="pmcaid">12872391</article-id><article-id pub-id-type="pmcaiid">12872391</article-id><article-id pub-id-type="pmid">41659993</article-id><article-id pub-id-type="doi">10.14218/JCTH.2025.00476</article-id><article-id pub-id-type="publisher-id">JCTH.2025.00476</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>ATP-binding Cassette Transporter Defects and Their Roles in Hepatic Diseases</article-title><alt-title alt-title-type="running-head-verso">Zhao D. <italic toggle="yes">et al</italic>: ABC mutations and associated liver diseases</alt-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Zhao</surname><given-names initials="D">Danzhu</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="COR1">*</xref><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0009-0009-0732-2209</contrib-id></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wu</surname><given-names initials="GY">George Y.</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><aff id="aff1"><label>1</label>Department of Medicine, University of Connecticut Health Center, Farmington, CT, USA</aff><aff id="aff2"><label>2</label>Department of Medicine, Division of Gastroenterology-Hepatology, University of Connecticut Health Center, Farmington, CT, USA</aff></contrib-group><author-notes><corresp id="COR1"><label>*</label><bold>Correspondence to:</bold> Danzhu Zhao, Department of Medicine, University of Connecticut Health Center, 263 Farmington Ave., Farmington, CT 06032, USA. ORCID: <ext-link ext-link-type="uri" xlink:href="https://orcid.org/0009-0009-0732-2209" xmlns:xlink="http://www.w3.org/1999/xlink">https://orcid.org/0009-0009-0732-2209</ext-link>. Tel: +1-360-790-1216, Fax: +1-860-679-6582, E-mail: <email>dazhao@uchc.edu</email>.</corresp><fn fn-type="financial-disclosure"><p>None to declare.</p></fn><fn fn-type="COI-statement"><p>GYW has been an Editor-in-Chief of the <italic toggle="yes">Journal of Clinical and Translational Hepatology</italic> since 2013. He has no role in the publisher’s decisions regarding this manuscript. DZ has no conflicts of interest related to this publication.</p></fn><fn fn-type="con"><p>Review concept (GYW), information collection, drafting of the manuscript (DZ), and revision of the manuscript (GYW, DZ). All authors have approved the final version and publication of the manuscript.</p></fn></author-notes><pub-date pub-type="ppub"><day>28</day><month>1</month><year>2026</year></pub-date><pub-date pub-type="epub"><day>18</day><month>12</month><year>2025</year></pub-date><volume>14</volume><issue>1</issue><issue-id pub-id-type="pmc-issue-id">506916</issue-id><fpage>50</fpage><lpage>58</lpage><history><date date-type="received"><day>14</day><month>9</month><year>2025</year></date><date date-type="rev-recd"><day>6</day><month>11</month><year>2025</year></date><date date-type="accepted"><day>19</day><month>11</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>18</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>06</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-12 16:25:13.123"><day>12</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© 2026 Authors.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbynclicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="JCTH-14-050.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><p>ATP-binding cassette (ABC) transporters are transmembrane proteins involved in the translocation of bilirubin, bile acids, phospholipids, and cholesterol into bile canaliculi. Mutations in particular genes encoding these transporters—including BSEP (<italic toggle="yes">ABCB11</italic> gene), MDR3 (<italic toggle="yes">ABCB4</italic> gene), sterolin-1 and sterolin-2 (<italic toggle="yes">ABCG5/8</italic> genes), and MRP2 (<italic toggle="yes">ABCC2</italic> gene)—result in a wide spectrum of liver diseases, ranging from benign conditions such as Dubin-Johnson syndrome to more severe presentations like progressive familial intrahepatic cholestasis. The severity of disease is influenced by many factors, including zygosity, mutation type, and environmental modifiers such as hormones, consanguinity, and founder effects. Homozygous and compound heterozygous mutations typically result in severe and early-onset diseases, while heterozygous single-allelic mutants generally result in milder diseases. Next-generation genetic testing has proven to have high diagnostic value and is important for prognostication. With knowledge of the underlying specific mutations, there is also potential for future targeted therapy for many severe diseases. The aim of this review is to update and discuss the hepatic diseases associated with ABC transporter mutations, the genetic and environmental effects that influence the severity of disease, typical presentations of these cholestatic hepatic diseases, diagnostic considerations, and treatment options.</p></abstract><kwd-group><kwd>ATP-binding cassette transporters</kwd><kwd>Cholestasis</kwd><kwd>Intrahepatic</kwd><kwd>Zygosity</kwd><kwd>Bile canaliculi</kwd><kwd>Next generation sequencing</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><title>Introduction</title><p>ATP-binding cassette (ABC) transporters are transmembrane proteins that move substrates across lipid membranes. ABC transporter proteins are categorized into seven families encoded by <italic toggle="yes">ABCA</italic> through <italic toggle="yes">ABCG</italic> genes (<xref ref-type="table" rid="JCTH-2025-00476-t1">Table 1</xref>). They are energized by ATP, which, when hydrolyzed, causes conformational change and induces transport.<xref ref-type="bibr" rid="JCTH-2025-00476-b1">1</xref> In mammals, ABC transporters are primarily in the liver, intestine, blood-brain barrier, placenta, and kidney.<xref ref-type="bibr" rid="JCTH-2025-00476-b2">2</xref></p><table-wrap id="JCTH-2025-00476-t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Relationship between zygosity of ABC mutations and corresponding phenotype(s)</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" colspan="1" rowspan="1">Gene (Transporter)</th><th align="left" colspan="1" rowspan="1">Zygosity</th><th align="left" colspan="1" rowspan="1">Associated disease(s)</th><th align="left" colspan="1" rowspan="1">Progression to cirrhosis</th></tr></thead><tbody><tr><td align="left" colspan="1" rowspan="1" valign="top"><italic toggle="yes">ABCB11</italic> (BSEP)</td><td align="left" colspan="1" rowspan="1" valign="top">Homozygous/Compound Heterozygous</td><td align="left" colspan="1" rowspan="1" valign="top">PFIC2 (severe cholestasis), early cirrhosis</td><td align="left" colspan="1" rowspan="1" valign="top">High</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Heterozygous</td><td align="left" colspan="1" rowspan="1" valign="top">BRIC2, ICP, OCC (transient/mild cholestasis)</td><td align="left" colspan="1" rowspan="1" valign="top">Low</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Biallelic Missense</td><td align="left" colspan="1" rowspan="1" valign="top">BRIC2 (variable severity, dependent on mutation type)</td><td align="left" colspan="1" rowspan="1" valign="top">Variable</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"><italic toggle="yes">ABCB4</italic> (MDR3)</td><td align="left" colspan="1" rowspan="1" valign="top">Homozygous/Compound Heterozygous</td><td align="left" colspan="1" rowspan="1" valign="top">PFIC3, neonatal cholestasis, liver cirrhosis, end-stage liver disease</td><td align="left" colspan="1" rowspan="1" valign="top">High</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Heterozygous</td><td align="left" colspan="1" rowspan="1" valign="top">LPAC, ICP, DILI, ductopenic cholestasis</td><td align="left" colspan="1" rowspan="1" valign="top">Low</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Heterozygous Missense (e.g., T175A, A250T, P352L)</td><td align="left" colspan="1" rowspan="1" valign="top">MDR3 deficiency (variable protein dysfunction)</td><td align="left" colspan="1" rowspan="1" valign="top">Variable (depends on variant and allele function)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"><italic toggle="yes">ABCG5</italic>/8 (Sterolin1/2)</td><td align="left" colspan="1" rowspan="1" valign="top">Homozygous/Compound Heterozygous</td><td align="left" colspan="1" rowspan="1" valign="top">Sitosterolemia (with/without liver disease), chronic hepatitis</td><td align="left" colspan="1" rowspan="1" valign="top">Possible (case-dependent)</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"><italic toggle="yes">ABCC2</italic> (MRP2)</td><td align="left" colspan="1" rowspan="1" valign="top">Homozygous</td><td align="left" colspan="1" rowspan="1" valign="top">DJS (cosmetic, hyperbilirubinemia), risk for drug toxicity.</td><td align="left" colspan="1" rowspan="1" valign="top">Rare</td></tr><tr><td align="left" colspan="1" rowspan="1" valign="top"/><td align="left" colspan="1" rowspan="1" valign="top">Heterozygous</td><td align="left" colspan="1" rowspan="1" valign="top">Mild abnormalities, altered excretion</td><td align="left" colspan="1" rowspan="1" valign="top">Rare to possible (especially with drug exposures)</td></tr></tbody></table><table-wrap-foot><fn id="nt101"><p>PFIC2, progressive familial intrahepatic cholestasis type 2; OCC, oral contraceptive-associated cholestasis; BRIC2, benign recurrent intrahepatic cholestasis type 2; DILI, drug-induced liver injury; ICP, intrahepatic cholestasis of pregnancy; LPAC, low phospholipid-associated cholestasis; DJS, Dubin-Johnson syndrome; MDR3, multidrug resistance 3; MRP2, multidrug resistance protein 2; sterolin 1/2, sterolin-1 and sterolin-2 heterodimer; BSEP, bile salt export pump.</p></fn></table-wrap-foot></table-wrap><p>The <italic toggle="yes">ABCB11</italic> gene on chromosome 2q24<xref ref-type="bibr" rid="JCTH-2025-00476-b3">3</xref> encodes the bile salt export pump (BSEP) on the canalicular membrane.<xref ref-type="bibr" rid="JCTH-2025-00476-b4">4</xref> Mutations can impair BSEP function, altering bile acid transport and causing cholestasis, as seen in <xref ref-type="fig" rid="JCTH-2025-00476-f1">Figure 1</xref>. More than 32,000 unique variants have been identified, including over 800 pathologic mutations of <italic toggle="yes">ABCB11</italic>.<xref ref-type="bibr" rid="JCTH-2025-00476-b5">5</xref>
<italic toggle="yes">ABCB11</italic> mutations have been linked to benign recurrent intrahepatic cholestasis (BRIC) type 2, intrahepatic cholestasis of pregnancy (ICP), oral contraceptive-induced cholestasis, and progressive familial intrahepatic cholestasis (PFIC) type 2.<xref ref-type="bibr" rid="JCTH-2025-00476-b6">6</xref> In PFIC, an excess of toxic intrahepatic bile acids is thought to be responsible for hepatocellular damage and possible progression to chronic liver disease<xref ref-type="bibr" rid="JCTH-2025-00476-b7">7</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b8">8</xref> as well as increased risk for hepatocellular carcinoma in the pediatric population.<xref ref-type="bibr" rid="JCTH-2025-00476-b9">9</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b10">10</xref></p><fig id="JCTH-2025-00476-f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><title>A diagram showing ABC transporters, their substrates, and the associated diseases that result from mutations in specific ABC transporters.</title><p>MDR3 defects are involved in the development of PFIC3, LPAC, ICP, and DILI. Sterolin 1/2 are cotransporters that transport plant sterols and can lead to sitosterolemia if mutated. MRP2 is responsible for the reuptake of conjugated bilirubin; mutations result in Dubin-Johnson syndrome. BSEP transports bile acids and is also located at the bile canalicular membrane. Mutations in this transporter are associated with PFIC2, BRIC2, ICP, and OCC. Created by BioRender. PFIC3, progressive familial intrahepatic cholestasis type 3; PFIC2, progressive familial intrahepatic cholestasis type 2; OCC, oral contraceptive-associated cholestasis; BRIC2, benign recurrent intrahepatic cholestasis type 2; DILI, drug-induced liver injury; ICP, intrahepatic cholestasis of pregnancy; LPAC, low phospholipid-associated cholestasis.</p></caption><graphic orientation="portrait" position="float" xlink:href="JCTH-14-050-g001.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>The <italic toggle="yes">ABCB4</italic> gene, located on chromosome 7, locus 21, encodes a phospholipid carrier protein, multidrug resistance 3 (MDR3<italic toggle="yes">)</italic>, which is a “floppase” that translocates phospholipids from the inner to the outer leaflet of canalicular membrane lipid bilayers to be extracted by bile salts.<xref ref-type="bibr" rid="JCTH-2025-00476-b11">11</xref>–<xref ref-type="bibr" rid="JCTH-2025-00476-b13">13</xref> Biliary phosphatidylcholine typically serves as a carrier and solvent of cholesterol by forming mixed micelles. Over 20,000 <italic toggle="yes">ABCB4</italic> gene variants have been identified, of which more than 600 are considered pathologic mutations.<xref ref-type="bibr" rid="JCTH-2025-00476-b14">14</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b15">15</xref> Mutations in the <italic toggle="yes">ABCB4</italic> gene result in decreased biliary phosphatidylcholine and decreased formation of simple micelles, as seen in <xref ref-type="fig" rid="JCTH-2025-00476-f1">Figure 1</xref>. <italic toggle="yes">ABCB4</italic> mutations in the adult population can present with intrahepatic cholelithiasis, PFIC3, ICP, or low phospholipid-associated cholestasis (LPAC) syndrome (<xref ref-type="table" rid="JCTH-2025-00476-t1">Table 1</xref>). MDR3 dysfunction results in decreased solubility of cholesterol in bile, ultimately resulting in increased cholesterol precipitation and gallstones.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref>
<italic toggle="yes">ABCB4</italic> mutations present with a broad spectrum of characteristics, including transient neonatal cholestasis, gallstones, liver cirrhosis, and end-stage liver disease.<xref ref-type="bibr" rid="JCTH-2025-00476-b17">17</xref></p><p>Because phosphatidylcholine is also protective to cholangiocyte epithelium, MDR3 dysfunction permits bile acid–mediated hepatocyte damage, which, if chronic, is associated with an increased risk of progression to secondary sclerosing cholangitis or biliary cirrhosis.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b18">18</xref>–<xref ref-type="bibr" rid="JCTH-2025-00476-b21">21</xref> Rare cases of cholangiocarcinoma have also been reported.<xref ref-type="bibr" rid="JCTH-2025-00476-b22">22</xref> Homozygous <italic toggle="yes">ABCB4</italic> cases usually present with more severe phenotypes, such as cirrhosis in pediatric patients. Heterozygous variants typically present in adults with features of PFIC.<xref ref-type="bibr" rid="JCTH-2025-00476-b23">23</xref></p><p><italic toggle="yes">ABCG5 and ABCG8</italic> genes in the <italic toggle="yes">STSL</italic> locus on chromosome 2p21 encode proteins sterolin-1 and sterolin-2, respectively, which together form a heterodimer pair expressed on the canalicular hepatocyte membrane and are involved in the transport of hepatobiliary cholesterol from hepatocytes into the bile canaliculi.<xref ref-type="bibr" rid="JCTH-2025-00476-b24">24</xref> Both sterolin-1 and sterolin-2 are synthesized in hepatocytes and form obligate heterodimers that translocate and embed in the hepatocyte apical membrane.<xref ref-type="bibr" rid="JCTH-2025-00476-b25">25</xref> Over 8,800 variants of <italic toggle="yes">ABCG5</italic> and approximately 480 mutations have been identified, while over 20,000 variants and greater than 600 mutations of <italic toggle="yes">ABCG8</italic> have been reported.<xref ref-type="bibr" rid="JCTH-2025-00476-b26">26</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b27">27</xref> Mutations in <italic toggle="yes">ABCG5</italic>/<italic toggle="yes">ABCG8</italic> result in elevated serum levels of cholesterol and other sterols, resulting in sitosterolemia (<xref ref-type="fig" rid="JCTH-2025-00476-f1">Fig. 1</xref>).<xref ref-type="bibr" rid="JCTH-2025-00476-b28">28</xref> Mutations of <italic toggle="yes">ABCG5</italic>/<italic toggle="yes">ABCG8</italic> in mice have been shown to reduce biliary cholesterol and increase cholesterol in the liver.<xref ref-type="bibr" rid="JCTH-2025-00476-b29">29</xref> Most patients with sitosterolemia have been found to have homozygous mutations.</p><p>The <italic toggle="yes">ABCC2</italic> gene is located on chromosome 10q24 and encodes the multidrug resistance-associated protein 2 (MRP2), a bile acid organic anion transporter involved in the transport of bilirubin and bile salts into bile (<xref ref-type="fig" rid="JCTH-2025-00476-f1">Fig. 1</xref>). MRP2 specifically excretes substances conjugated with glutathione, sulfate, and glucuronate and contributes to biliary flow.<xref ref-type="bibr" rid="JCTH-2025-00476-b30">30</xref> Over 1,000 <italic toggle="yes">ABCC2</italic> mutations have been identified.<xref ref-type="bibr" rid="JCTH-2025-00476-b31">31</xref> Deletion, missense, nonsense, and splice junction mutations have been identified as alterations to the <italic toggle="yes">ABCC2</italic> gene, leading to Dubin-Johnson syndrome (DJS). Autosomal recessive <italic toggle="yes">ABCC2</italic> mutations result in DJS with increased serum bilirubin glucuronides. Heterozygous individuals with <italic toggle="yes">ABCC2</italic> mutations are typically asymptomatic, whereas homozygous or compound heterozygous individuals developisolated elevation of conjugated hyperbilirubinemia.<xref ref-type="bibr" rid="JCTH-2025-00476-b7">7</xref></p><p>Zygosity of mutations in ABC genes appears to be a major determinant for the observed spectrum of disease (<xref ref-type="table" rid="JCTH-2025-00476-t1">Table 1</xref>).<xref ref-type="bibr" rid="JCTH-2025-00476-b32">32</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref> This refers to homozygous versus heterozygous genetic pairing of alleles, the former indicating two identical mutant alleles and the latter indicating a mutant and a normal allele. A compound heterozygote represents the presence of different (non-identical) mutant variants of alleles and can also lead to severe presentations. Genetic dosing refers to the number of mutant alleles (mono- versus biallelic), which often correlates with the severity of disease expression.</p><p>Severe cases of <italic toggle="yes">ABCB11</italic> defects that lead to PFIC2 are most often biallelic (homozygous or compound heterozygous) variants.<xref ref-type="bibr" rid="JCTH-2025-00476-b34">34</xref> In heterozygous (monoallelic) <italic toggle="yes">ABCB4</italic> transporter mutations, the phenotype is typically less severe, as in LPAC, ICP, ductopenic cholestatic liver disease, and drug-induced liver injury.<xref ref-type="bibr" rid="JCTH-2025-00476-b35">35</xref>–<xref ref-type="bibr" rid="JCTH-2025-00476-b37">37</xref> Gord-Gilart <italic toggle="yes">et al</italic>. studied heterozygous <italic toggle="yes">ABCB4</italic> missense variants in a pediatric population of 67 patients with chronic cholestasis and features of MDR3 deficiency and found various degrees of protein dysfunction. <italic toggle="yes">ABCB4</italic> variant T175A led to a 65.5% decrease in MDR3 activity, A250T had a 90% reduction of activity, and P352L resulted in reduced protein levels, suggesting different variants have specific functional consequences. Approximately 50% of MDR3 expression and function is presumed to be contributed by a normal allele in heterozygous individuals.<xref ref-type="bibr" rid="JCTH-2025-00476-b35">35</xref> Homozygous (biallelic) <italic toggle="yes">ABCB4</italic> transporter mutations and compound heterozygous mutations lead to higher rates of progression to cirrhosis, as seen in PFIC3.<xref ref-type="bibr" rid="JCTH-2025-00476-b23">23</xref></p><p>Studies have shown that biallelic mutations do not always result in severe cholestatic disease, as they are dependent on the type of mutation (e.g., missense, truncating, splicing) and can be influenced by extrinsic environmental factors.<xref ref-type="bibr" rid="JCTH-2025-00476-b38">38</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b39">39</xref> Biallelic missense mutations can sometimes result in less severe presentations compared to truncating and splicing mutations.<xref ref-type="bibr" rid="JCTH-2025-00476-b39">39</xref> For example, Al-Hussaini <italic toggle="yes">et al</italic>. studied 65 pediatric patients with PFIC1–3 cholestatic disease and identified 27 different mutations that resulted in defective <italic toggle="yes">ATP8B1</italic>, <italic toggle="yes">ABCB11</italic>, and <italic toggle="yes">ABCB4</italic>. Of the 35 patients with <italic toggle="yes">ABCB11</italic> mutations, four with heterozygous missense mutations in <italic toggle="yes">ABCB11</italic> had transient PFIC2-associated cholestasis.<xref ref-type="bibr" rid="JCTH-2025-00476-b39">39</xref> Compound heterozygous missense mutations, on the other hand, have been shown to cause early-onset, severe, and progressive PFIC2-associated liver disease.<xref ref-type="bibr" rid="JCTH-2025-00476-b40">40</xref> Frameshift, homozygous splicing, and nonsense mutations developed severe phenotypes of PFIC2.<xref ref-type="bibr" rid="JCTH-2025-00476-b40">40</xref></p><p>The aim of this review is to provide an update on the diverse genetics, phenotypic presentations, diagnosis, and treatment of ABC transporter mutation-associated diseases.</p></sec><sec id="s2"><title>Specific diseases caused by <italic toggle="yes">ABCB11</italic> mutations: ICP, BRIC, and PFIC2</title><p>Mutations of <italic toggle="yes">ABCB11</italic> encoding BSEP can give rise to a spectrum of cholestatic disorders of varying severity.</p><sec id="s2a"><title>ICP</title><sec id="s2a1"><title>Epidemiology</title><p>The prevalence of <italic toggle="yes">ABCB11</italic> mutation is not certain. The incidence has been estimated to be between 1/50,000 and 1/100,000.<xref ref-type="bibr" rid="JCTH-2025-00476-b3">3</xref> This accounts for 37.5%–90.0% of cholestatic patients.<xref ref-type="bibr" rid="JCTH-2025-00476-b41">41</xref>
<italic toggle="yes">ABCB11</italic> mutations have been primarily identified in European and American populations.<xref ref-type="bibr" rid="JCTH-2025-00476-b42">42</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b43">43</xref></p><p>The prevalence of ICP has been reported to range from 0.3%–5.6% and the incidence from 0.1% to 15.6%.<xref ref-type="bibr" rid="JCTH-2025-00476-b44">44</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b45">45</xref> A meta-analysis showed a significantly increased risk for ICP in patients with pre-existing hepatobiliary disease (pooled risk ratio: 2.81, 95% confidence interval: 2.66–2.97, <italic toggle="yes">P</italic> &lt; 0.00001).<xref ref-type="bibr" rid="JCTH-2025-00476-b46">46</xref></p></sec><sec id="s2a2"><title>Presentation</title><p>ICP typically presents in the second trimester of pregnancy with generalized pruritus, more commonly located on the palms and soles in 25% of patients.<xref ref-type="bibr" rid="JCTH-2025-00476-b47">47</xref> Symptoms of pruritus are typically worse in the evenings.<xref ref-type="bibr" rid="JCTH-2025-00476-b47">47</xref> Only about 10% of patients with pruritus develop icterus.<xref ref-type="bibr" rid="JCTH-2025-00476-b47">47</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b48">48</xref> Other symptoms, such as fatigue, nausea, vomiting, right upper quadrant abdominal pain, dark urine, and pale stools, may also be present.<xref ref-type="bibr" rid="JCTH-2025-00476-b49">49</xref> Symptoms generally resolve after delivery of the fetus but can persist for up to one to two weeks.<xref ref-type="bibr" rid="JCTH-2025-00476-b47">47</xref> Excoriation from pruritus in pregnant individuals is typically seen on physical exam.<xref ref-type="bibr" rid="JCTH-2025-00476-b49">49</xref></p><p>While maternal symptoms are troublesome, the main medical concern of ICP is poor fetal outcomes, including preterm delivery in 19%–60%,<xref ref-type="bibr" rid="JCTH-2025-00476-b21">21</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b50">50</xref> fetal distress in 22%–41%,<xref ref-type="bibr" rid="JCTH-2025-00476-b50">50</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b51">51</xref> and intrauterine fetal death in 0.8%–1.6% of ICP pregnancies.<xref ref-type="bibr" rid="JCTH-2025-00476-b48">48</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b50">50</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b51">51</xref> Fetal risks increase with increasing levels of maternal serum bile acids.<xref ref-type="bibr" rid="JCTH-2025-00476-b52">52</xref>–<xref ref-type="bibr" rid="JCTH-2025-00476-b54">54</xref></p></sec><sec id="s2a3"><title>Diagnosis</title><p>ICP is diagnosed by the presence of pruritus in the second trimester. The combination of pruritus and an increase in serum bile acids is highly suggestive of ICP.<xref ref-type="bibr" rid="JCTH-2025-00476-b47">47</xref> Blood tests, including total serum bile acid level greater than 10 µmol/L<xref ref-type="bibr" rid="JCTH-2025-00476-b54">54</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b55">55</xref> and elevated aminotransferases, support the diagnosis of ICP in the absence of other causes of cholestasis.<xref ref-type="bibr" rid="JCTH-2025-00476-b54">54</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b56">56</xref> Severe ICP, in which there is an increased risk for fetal complications, has been associated with higher levels of serum bile acids &gt; 40 µmol/L.<xref ref-type="bibr" rid="JCTH-2025-00476-b52">52</xref>–<xref ref-type="bibr" rid="JCTH-2025-00476-b54">54</xref> Serum bile acid and alanine aminotransferase (ALT) due to ICP return to normal ranges within three weeks postpartum.<xref ref-type="bibr" rid="JCTH-2025-00476-b54">54</xref> Ultrasound imaging is generally used to exclude other causes of cholestasis. Liver biopsy is rarely needed.<xref ref-type="bibr" rid="JCTH-2025-00476-b54">54</xref> Genetic testing is not routinely recommended for the diagnosis of ICP.</p></sec><sec id="s2a4"><title>Treatment</title><p>Ursodeoxycholic acid (UDCA) has been shown to significantly improve ICP-related pruritus and decrease mean bile acid levels by 79%, bilirubin levels by 50%, and ALT by 80%, <italic toggle="yes">P</italic> ≤ 0.01.<xref ref-type="bibr" rid="JCTH-2025-00476-b57">57</xref> In addition, because UDCA creates a more hydrophilic component to bile acids, bile acid-induced hepatotoxicity and mitochondrial integrity are ameliorated.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b59">59</xref> Bacq <italic toggle="yes">et al</italic>. found improvement of serum ALT in 65.9% of patients with ICP after UDCA treatment compared to 20% (<italic toggle="yes">P</italic> &lt; 0.0001) for placebo, and normalization of serum ALT was observed in 27.8% with UDCA but only 14.3% with placebo (<italic toggle="yes">P</italic> &lt; 0.001). Bile acid levels improved in 54.3% of ICP patients on UDCA treatment compared to 18.6% on placebo (<italic toggle="yes">P</italic> &lt; 0.01).<xref ref-type="bibr" rid="JCTH-2025-00476-b57">57</xref></p><p>Cholestyramine binds to bile acids in the gut, preventing reabsorption of bile acids and reducing bile acid levels, and is recommended to treat pruritus. Recent evidence suggests that pruritogens such as lysophosphatidic acid, sulfated progesterone metabolites, and autotaxin bind to neuroreceptors such as MRGPRX4 that trigger pruritus.<xref ref-type="bibr" rid="JCTH-2025-00476-b60">60</xref> Cholestyramine does not directly affect these receptors<xref ref-type="bibr" rid="JCTH-2025-00476-b60">60</xref> and, therefore, only provides partial relief by preventing bile acid accumulation.<xref ref-type="bibr" rid="JCTH-2025-00476-b61">61</xref> Cholestyramine has been reported to be less effective than UDCA in improving serum aspartate aminotransferase (AST) and ALT (21.4% compared to &gt;70%, <italic toggle="yes">P</italic> &lt; 0.01) and pruritus (66.6% vs. 19.0%, respectively; <italic toggle="yes">P</italic> &lt; 0.005).<xref ref-type="bibr" rid="JCTH-2025-00476-b62">62</xref></p></sec></sec><sec id="s2b"><title>BRIC</title><sec id="s2b1"><title>Epidemiology</title><p>Data on the prevalence of BRIC are not available, but it has been reported to be less prevalent than PFIC2.<xref ref-type="bibr" rid="JCTH-2025-00476-b63">63</xref></p></sec><sec id="s2b2"><title>Presentation</title><p>BRIC can present at any age, though it typically presents by the age of 20 years with recurrent episodes lasting weeks to months.<xref ref-type="bibr" rid="JCTH-2025-00476-b64">64</xref> BRIC is characterized by acute onset of recurrent bouts (at least two episodes) of cholestasis that present as jaundice and severe pruritus, with periods of no symptoms for weeks to years,<xref ref-type="bibr" rid="JCTH-2025-00476-b65">65</xref> and normal laboratory and histology findings during the intervening periods.<xref ref-type="bibr" rid="JCTH-2025-00476-b59">59</xref> Patients may have prodromal symptoms such as fatigue, poor appetite, and nausea, accompanied by weight loss.<xref ref-type="bibr" rid="JCTH-2025-00476-b65">65</xref> The recurrence of symptoms in young patients with asymptomatic periods should raise suspicion for BRIC.</p></sec><sec id="s2b3"><title>Diagnosis</title><p>BRIC is diagnosed by the presence of cholestasis with severe pruritus and at least two episodes of jaundice interspersed with asymptomatic periods. Typical laboratory findings include elevated serum conjugated bilirubin, alkaline phosphatase with normal GGT levels, and normal bile ducts on imaging. Liver biopsy is usually unnecessary.<xref ref-type="bibr" rid="JCTH-2025-00476-b66">66</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b67">67</xref> Next-generation sequencing (NGS) remains the gold standard in differentiating BRIC from PFIC2.<xref ref-type="bibr" rid="JCTH-2025-00476-b59">59</xref></p></sec><sec id="s2b4"><title>Treatment</title><p>Cholestyramine and UDCA are common treatment options for pruritus from BRIC. Rifampicin has also been reported to reduce pruritus and abort cholestatic episodes by activation of the nuclear pregnane X receptor and induction of bile acid sulfation.<xref ref-type="bibr" rid="JCTH-2025-00476-b59">59</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b68">68</xref> Alternatively, endoscopic nasobiliary drainage has been provided as a method to decompress bile in the common bile duct, resolving pruritus and jaundice.<xref ref-type="bibr" rid="JCTH-2025-00476-b59">59</xref> Fibrates that inhibit bile acid synthesis and improve bile excretion may also be a treatment option.<xref ref-type="bibr" rid="JCTH-2025-00476-b69">69</xref> Ileal bile acid transport inhibitors have recently also been used as BRIC therapy.<xref ref-type="bibr" rid="JCTH-2025-00476-b70">70</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b71">71</xref></p></sec></sec><sec id="s2c"><title>PFIC2</title><sec><title>Epidemiology</title><p>The incidence of <italic toggle="yes">ABCB11</italic> mutations has been estimated to be between 1/50,000 and 1/100,000, with approximately half of the cases represented by PFIC2.<xref ref-type="bibr" rid="JCTH-2025-00476-b3">3</xref></p></sec><sec id="s2c1"><title>Presentation</title><p>The p.Val444A1a variant of <italic toggle="yes">ABCB11</italic> mutation accounts for 50% of BSEP transport dysfunction. Once BSEP activity falls below 20%–25%, liver damage usually occurs due to biallelic loss-of-function causing PFIC2. Onset can occur in adulthood, but PFIC2 typically presents in neonatal/early infancy.<xref ref-type="bibr" rid="JCTH-2025-00476-b72">72</xref> Because of this early presentation, end-stage liver disease and development of hepatocellular malignancy may occur before the age of 1 year.<xref ref-type="bibr" rid="JCTH-2025-00476-b3">3</xref> Heterozygous individuals are often spared chronic liver injury.<xref ref-type="bibr" rid="JCTH-2025-00476-b73">73</xref> Baker <italic toggle="yes">et al</italic>. reported that jaundice, pruritus, hepatomegaly, splenomegaly, and discolored stools were the most common clinical presentations of PFIC2.<xref ref-type="bibr" rid="JCTH-2025-00476-b41">41</xref> Davit-Spraul <italic toggle="yes">et al</italic>. studied 36 patients with PFIC2 and found that 100% of the patients developed pruritus, 97% developed hepatomegaly, and 41% had splenomegaly. Jaundice presented in 11% on presentation.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref> Symptoms have been reported to appear within the first month of life in 44% of PFIC2 patients.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref> Excoriation and hyperpigmentation of the skin were common physical findings. In severe cases, portal hypertension can develop by one year of age.<xref ref-type="bibr" rid="JCTH-2025-00476-b72">72</xref> Early onset of jaundice is a commonly used indication for workup for possible PFIC2 after exclusion of common causes of hyperbilirubinemia in infancy.<xref ref-type="bibr" rid="JCTH-2025-00476-b74">74</xref></p><p>PFIC2 defects may result in fat-soluble vitamin deficiencies and coagulopathy (vitamin K), ataxia and peripheral neuropathy (vitamin E), rickets or osteomalacia (vitamin D), and/or night vision issues and xerophthalmia (vitamin A).<xref ref-type="bibr" rid="JCTH-2025-00476-b75">75</xref> Compared to PFIC1 (<italic toggle="yes">ATP8B1</italic> mutation), PFIC2 presents with more severe and persistent cholestasis.<xref ref-type="bibr" rid="JCTH-2025-00476-b72">72</xref></p></sec><sec id="s2c2"><title>Diagnosis</title><p>PFIC2 cases typically have elevated conjugated bilirubin levels without elevated GGT because PFIC2 affects the BSEP without damaging the bile duct epithelium, where GGT is produced. Ultrasonography is helpful in excluding surgical causes for cholestasis, such as choledochal cysts or biliary atresia.<xref ref-type="bibr" rid="JCTH-2025-00476-b76">76</xref> NGS confirms the diagnosis and remains the gold standard for diagnosis.<xref ref-type="bibr" rid="JCTH-2025-00476-b59">59</xref> Liver histology of PFIC2 may show hepatocellular necrosis, giant cell transformation, and evidence of cirrhosis.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref> Immunostaining for MDR3 and BSEP antibodies can permit differentiation between PFIC2 and PFIC3 because BSEP expression is markedly reduced in PFIC2, but preserved in PFIC3. The opposite would be expected for MDR3 staining.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref> While liver biopsy can be helpful in providing supportive findings, it is not required to diagnose PFIC2, as genetic testing remains the gold standard.<xref ref-type="bibr" rid="JCTH-2025-00476-b74">74</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b76">76</xref></p></sec><sec id="s2c3"><title>Treatment</title><p>PFIC2 is often treated initially with UDCA. Phenobarbital can be used to treat neonatal hyperbilirubinemia through CYP enzyme UDP-glucuronosyltransferase induction.<xref ref-type="bibr" rid="JCTH-2025-00476-b74">74</xref> Partial internal biliary drainage reduces the circulation of bile salts and decreases accumulation of bile salts. Partial internal biliary drainage is the gold standard therapy for non-cirrhotic, low-GGT cholestatic disease as seen in <italic toggle="yes">ABCB11</italic> mutations when unremitting pruritus is present. Partial external biliary diversion requires a permanent stoma. Therefore, ileal exclusion or partial internal biliary diversion methods have been proposed, but there are limited data on long-term outcomes.<xref ref-type="bibr" rid="JCTH-2025-00476-b77">77</xref> Ileal bypass procedures have also been utilized in those with prior cholecystectomy. However, long-term efficacy remains unknown.<xref ref-type="bibr" rid="JCTH-2025-00476-b74">74</xref> If these options fail, liver transplantation is the recommended alternative.<xref ref-type="bibr" rid="JCTH-2025-00476-b74">74</xref></p></sec></sec></sec><sec id="s3"><title>Specific diseases caused by <italic toggle="yes">ABCB4</italic> mutations: ICP, LPAC, and PFIC3</title><p>Mutations in the <italic toggle="yes">ABCB4</italic> gene encoding MDR3 are responsible for several cholestatic liver diseases, including ICP, LPAC, and PFIC3.</p><sec id="s3a"><title>ICP</title><p>As discussed above, predisposed women with mutations in <italic toggle="yes">ABCB11</italic> develop decreased BSEP activity due to elevated estrogens during pregnancy and share a similar mechanism with mono-allelic <italic toggle="yes">ABCB4</italic> mutations. The <italic toggle="yes">ABCB4</italic> biallelic form is generally a more severe form of ICP and is associated with progression to liver cirrhosis and end-stage liver disease.<xref ref-type="bibr" rid="JCTH-2025-00476-b18">18</xref></p></sec><sec id="s3b"><title>LPAC</title><sec id="s3b1"><title>Epidemiology</title><p>LPAC syndrome is rare, with prevalence reportedly less than 5% of patients with cholelithiasis.<xref ref-type="bibr" rid="JCTH-2025-00476-b78">78</xref> Studies have suggested LPAC is present in 1% of adult patients with symptomatic cholelithiasis.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b79">79</xref> LPAC has been reported to occur in a female-to-male ratio of nearly 3:1.<xref ref-type="bibr" rid="JCTH-2025-00476-b80">80</xref></p></sec><sec id="s3b2"><title>Presentation</title><p>LPAC presents with recurrent biliary symptoms, typically before age 40, and with persistent recurrent symptoms despite cholecystectomy.<xref ref-type="bibr" rid="JCTH-2025-00476-b23">23</xref> In a study of 308 patients with LPAC, 95% experienced biliary colic.<xref ref-type="bibr" rid="JCTH-2025-00476-b79">79</xref> Recurrence of biliary symptoms after cholecystectomy was reported in 86% of patients with LPAC, so this history should raise clinical suspicion for LPAC.<xref ref-type="bibr" rid="JCTH-2025-00476-b79">79</xref> Patients diagnosed with <italic toggle="yes">ABCB4</italic> mutations as adults were observed to have less severe phenotypes, such as ICP and LPAC.<xref ref-type="bibr" rid="JCTH-2025-00476-b23">23</xref></p></sec><sec id="s3b3"><title>Diagnosis</title><p>LPAC diagnosis is made based on two of three diagnostic criteria: recurrent symptoms despite cholecystectomy, presence of hyperechogenic intrahepatic foci, sludge or microlithiasis on ultrasound, and/or age of onset less than 40 years.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref> Imaging with ultrasonography of the liver is crucial in identifying intrahepatic sludge, microlithiasis, and hyperechoic foci with acoustic shadowing.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref> Biopsy findings are variable and nonspecific and not required for diagnosis.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref> Although <italic toggle="yes">ABCB4</italic> gene mutation identification with NGS is helpful in supporting diagnosis, its absence does not exclude LPAC, as 56<italic toggle="yes">%</italic>–65% of cases may lack <italic toggle="yes">ABCB4</italic> gene mutations.<xref ref-type="bibr" rid="JCTH-2025-00476-b16">16</xref></p></sec><sec id="s3b4"><title>Treatment</title><p>UDCA is the preferred treatment for LPAC. Prevention by prophylactically treating with UDCA has proven effective in reducing recurrence.<xref ref-type="bibr" rid="JCTH-2025-00476-b80">80</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b81">81</xref></p></sec></sec><sec id="s3c"><title>PFIC3</title><sec id="s3c1"><title>Epidemiology</title><p>The prevalence of PFIC3 has not been determined with certainty.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref> Nearly 1/3 of PFIC cases involve PFIC3.<xref ref-type="bibr" rid="JCTH-2025-00476-b82">82</xref> There does not appear to be a sex predominance.<xref ref-type="bibr" rid="JCTH-2025-00476-b72">72</xref></p></sec><sec id="s3c2"><title>Presentation</title><p>Biallelic mutations of <italic toggle="yes">ABCB4</italic> are associated with severe pediatric liver disease such as PFIC3. PFIC3 typically presents in infancy to early adulthood.<xref ref-type="bibr" rid="JCTH-2025-00476-b72">72</xref> Schatz <italic toggle="yes">et al</italic>. studied 38 PFIC3 patients with homozygous or heterozygous <italic toggle="yes">ABCB4</italic> mutations and identified 26 patients with pruritus. Of these, 85% presented with hepatomegaly and 96% with splenomegaly. Jaundice was seen in 62% of patients, and portal hypertension was noted in 69%.<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref> PFIC3 can present with pruritus, although it is often less severe than PFIC2. Extrahepatic manifestations are uncommon.<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref> Pediatric and early adult patients with unexplained cholestatic symptoms should be considered for a PFIC3 workup.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref></p></sec><sec id="s3c3"><title>Diagnosis</title><p>Diagnosis of PFIC3 is made by finding conjugated hyperbilirubinemia, including elevated serum ALT, alkaline phosphatase, and serum GGT. GGT was found to be increased in all patients; ALT was increased in 78.3%, AST in 91.3%, total bilirubin in nearly 70%, direct bilirubin in 73.9%, and total bile acid in 87%. Serum fasting bile acids were also typically elevated, while biliary concentrations remained in the normal range.<xref ref-type="bibr" rid="JCTH-2025-00476-b11">11</xref> Cao <italic toggle="yes">et al</italic>. analyzed 23 patients, 14 of whom with <italic toggle="yes">ABCB4</italic> biallelic gene-related cholestatic liver disease were diagnosed as PFIC3, while the remaining variants were diagnosed with ICP, LPAC, or drug-induced liver injury. They also found liver fibrosis by abdominal ultrasound, CT, and/or MRI in all patients. Liver biopsies obtained in 19 patients revealed small bile duct hyperplasia in nearly 85%, copper staining in 42.1%, and cirrhotic changes in 63.2%.<xref ref-type="bibr" rid="JCTH-2025-00476-b14">14</xref> Inflammatory infiltrates periportally with evidence of fibrosis and giant-cell transformation were also seen. Cholesterol crystals in bile ducts, with features of chronic cholangiopathy and cholesterol clefts, have been described.<xref ref-type="bibr" rid="JCTH-2025-00476-b11">11</xref></p><p>Using comprehensive bile acid profiling, tauro-tetrahydroxylated bile acid levels have been reported to be of value in predicting the clinical outcome of low-GGT intrahepatic cholestasis patients.<xref ref-type="bibr" rid="JCTH-2025-00476-b83">83</xref> Genetic analysis utilizing<xref ref-type="bibr" rid="JCTH-2025-00476-b84">84</xref> non-translated regions may be under-detected.<xref ref-type="bibr" rid="JCTH-2025-00476-b84">84</xref></p></sec><sec id="s3c4"><title>Treatment</title><p>UDCA is the first-line therapy in PFIC3. Rifampicin and cholestyramine may also be used for management of pruritus.<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref> Pharmacologic agents that target <italic toggle="yes">ABCB4</italic> gene transcription induction by farnesoid X receptor (FXR) agonists or peroxisome proliferator-activated receptor (PPAR)-α ligands have been suggested as potential second-line options.<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref></p><p>Management for <italic toggle="yes">ABCB4</italic> gene mutations includes ensuring dietary fat and fat-soluble vitamins are supplemented appropriately, particularly vitamin D, as studies have shown vitamin D deficiency in mouse models led to worsened liver fibrosis, suggesting possible protective benefit.<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref></p><p>Liver transplantation may be considered in patients with end-stage liver disease, HCC, or in those who are not responsive to medical therapies.</p></sec></sec></sec><sec id="s4"><title>Specific diseases caused by <italic toggle="yes">ABCG5</italic> and <italic toggle="yes">ABCG8</italic> gene defects: Sitosterolemia</title><p>In contrast to bile acid and phospholipid transporters discussed above, <italic toggle="yes">ABCG5</italic> and <italic toggle="yes">ABCG8</italic> gene mutations primarily disrupt sterol homeostasis. Loss of function in the encoded transporters results in impaired biliary cholesterol efflux, clinically recognized as sitosterolemia.</p><sec id="s4a"><title>Sitosterolemia</title><sec id="s4a1"><title>Epidemiology</title><p><italic toggle="yes">ABCG5</italic> and <italic toggle="yes">ABCG8</italic> gene variants have been reported to range between 5% and 30% in the general population.<xref ref-type="bibr" rid="JCTH-2025-00476-b24">24</xref> However, sitosterolemia is rare, with a reported prevalence of one in about 200,000 having homozygous or compound heterozygous mutations.<xref ref-type="bibr" rid="JCTH-2025-00476-b85">85</xref></p></sec><sec id="s4a2"><title>Presentation</title><p>Sitosterolemia is characterized by elevated serum levels of plasma plant sterols and cholesterol. Patients may have the classic presentation of tendinous and tuberous xanthomas and premature coronary atherosclerosis.<xref ref-type="bibr" rid="JCTH-2025-00476-b86">86</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b87">87</xref> Do <italic toggle="yes">et al</italic>. studied the presentations of 14 pediatric patients with sitosterolemia and observed xanthomas in 85.7% of patients, located in the elbow joint, buttocks, knees, ankle creases, wrist, and extensor surfaces. Arthralgia was present in 14.3% of patients.</p><p>This presentation may simulate that of familial hypercholesterolemia, although tendon xanthomas have been reported to be more severe in sitosterolemia than in heterozygous familial hypercholesterolemia. Patients with sitosterolemia may also present with hemolytic anemia, macrothrombocytopenia, and splenomegaly as a result of elevated sterol concentration in blood cell membranes.<xref ref-type="bibr" rid="JCTH-2025-00476-b88">88</xref></p></sec><sec id="s4a3"><title>Diagnosis</title><p>Sitosterolemia can be diagnosed by clinical manifestations, a plasma concentration of sitosterol above 1 mg/dL, cerebrotendinous xanthomatosis, and confirmation of <italic toggle="yes">ABCG5</italic> and <italic toggle="yes">ABCG8</italic> mutations by NGS.<xref ref-type="bibr" rid="JCTH-2025-00476-b85">85</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b89">89</xref> Kidambi <italic toggle="yes">et al</italic>. found sitosterol concentrations as high as 65 mg/dL.<xref ref-type="bibr" rid="JCTH-2025-00476-b58">58</xref> Noninvasive coronary and carotid plaque management is often needed due to its significant impact on the cardiovascular system.<xref ref-type="bibr" rid="JCTH-2025-00476-b89">89</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b90">90</xref></p></sec><sec id="s4a4"><title>Treatment</title><p>First-line treatment for sitosterolemia is avoidance of plant sterol-rich foods, including corn oil, sesame oil, margarine, avocado, peanuts, soybeans, among other fruits and vegetables. Cholesterol-rich foods should also be avoided.</p><p>Pharmacologic therapies such as ezetimibe and bile-acid sequestrant resins are recommended to help reduce sitosterol and lower LDL cholesterol levels. HMG-CoA reductase activity is inhibited in sitosterolemia. Therefore, statin therapy is not recommended for primary preventative therapy, although it can be used in possibly reducing atherosclerotic cardiovascular risks. Liver transplantation has been reported for treatment of sitosterolemia-induced liver cirrhosis.<xref ref-type="bibr" rid="JCTH-2025-00476-b91">91</xref></p></sec></sec></sec><sec id="s5"><title>Specific diseases caused by <italic toggle="yes">ABCC2</italic> gene defects</title><sec id="s5a"><title>DJS</title><sec id="s5a1"><title>Epidemiology</title><p>More than 50 mutations in MRP2 have been associated with DJS.<xref ref-type="bibr" rid="JCTH-2025-00476-b14">14</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b15">15</xref> There is no known ethnic predisposition to DJS, although Sephardic Jews have been noted to have a higher frequency of disease burden.<xref ref-type="bibr" rid="JCTH-2025-00476-b92">92</xref> The estimated prevalence of DJS is 1/1,300 individuals. DJS cases have primarily been reported as case reports.<xref ref-type="bibr" rid="JCTH-2025-00476-b93">93</xref></p></sec><sec id="s5a2"><title>Presentation</title><p>DJS typically presents with asymptomatic mild jaundice and dark urine without pruritus. Abdominal pain and weakness have been rarely reported.<xref ref-type="bibr" rid="JCTH-2025-00476-b94">94</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b95">95</xref></p></sec><sec id="s5a3"><title>Diagnosis</title><p>DJS presents with jaundice due to conjugated hyperbilirubinemia without hemolysis. Patients typically have elevated total bilirubin levels (2–5 mg/dL), while ALT, AST, alkaline phosphatase, and complete blood count remain normal. Although bilirubin levels are usually only mildly elevated, levels as high as 19 mg/dL have been reported.<xref ref-type="bibr" rid="JCTH-2025-00476-b96">96</xref> Urinary coproporphyrin levels are elevated, of which 80% are coproporphyrin I isomers. Normally, 75% of urinary coproporphyrin consists of isomer III.<xref ref-type="bibr" rid="JCTH-2025-00476-b96">96</xref> Cholescintigraphy can show delayed bromsulfthalein uptake and very slow excretion from hepatocytes, with visualization of the hepatobiliary tract. However, imaging is usually unnecessary to diagnose DJS. Liver biopsy is not required for the diagnosis of DJS. However, liver histology has been reported to reveal pigment deposits in lysosomes of hepatocytes.<xref ref-type="bibr" rid="JCTH-2025-00476-b97">97</xref></p></sec><sec id="s5a4"><title>Treatment</title><p>DJS is a benign disease and, therefore, does not pose a risk for progressive disease. Phenobarbital and UDCA can be considered in the management of cholestasis in neonatal DJS.<xref ref-type="bibr" rid="JCTH-2025-00476-b98">98</xref> Because many medications are normally eliminated by the hepatic MRP2 exporter, DJS patients should be advised regarding possible risk of excess blood levels of medications due to decreased hepatic elimination.<xref ref-type="bibr" rid="JCTH-2025-00476-b98">98</xref></p></sec></sec></sec><sec id="s6"><title>Discussion</title><p>ABC transporter genetic defects, in combination with environmental factors, affect clinical presentations and disease severity.<xref ref-type="bibr" rid="JCTH-2025-00476-b99">99</xref> For example, reproductive hormones such as estrogen and progesterone significantly influence the cholestatic presentation of ICP when hormone levels peak in the third trimester of pregnancy and in subsequent pregnancies.<xref ref-type="bibr" rid="JCTH-2025-00476-b100">100</xref> Studies have demonstrated that progestin administration in patients with threatened preterm labor is associated with a significantly higher risk of ICP.<xref ref-type="bibr" rid="JCTH-2025-00476-b101">101</xref>–<xref ref-type="bibr" rid="JCTH-2025-00476-b103">103</xref> Tsur <italic toggle="yes">et al</italic>. studied over 800,000 pregnancies and found that vaginal progesterone use in the second and third trimesters was associated with a significantly increased risk for cholestasis compared to no progesterone therapy (odds ratio 3.16).<xref ref-type="bibr" rid="JCTH-2025-00476-b102">102</xref> 17α-estradiol can also induce ICP by inhibiting the activity of BSEP.<xref ref-type="bibr" rid="JCTH-2025-00476-b104">104</xref> Medications such as cyclosporine A, bosentan, oral contraceptives, and cyclosporine have been reported to inhibit ABC transporter BSEP or MDR3 function and lead to cholestatic patterns that present as drug-induced liver injury.<xref ref-type="bibr" rid="JCTH-2025-00476-b105">105</xref></p><p>ABC transporter mutations can be suspected based on clinical presentation and laboratory findings, but genetic testing is the gold standard for the diagnosis of most inherited cholestatic diseases. Studies have found that nearly half of patients with unexplained cholestatic liver disease after standard diagnostic workup had detectable gene variants for PFIC mutations in the <italic toggle="yes">ABCB4</italic> and <italic toggle="yes">ABCB11</italic> genes.<xref ref-type="bibr" rid="JCTH-2025-00476-b20">20</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b106">106</xref></p><p>Individuals with early-onset and progressive liver disease, unexplained cholestasis, ICP, LPAC, drug-induced cholestasis, or a family history of cholestatic diseases should consider genetic testing for ABC transporter mutations.<xref ref-type="bibr" rid="JCTH-2025-00476-b73">73</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b107">107</xref></p><p>Several genetic tests are available, ranging from targeted panels to more comprehensive genome testing. These include Sanger sequencing, NGS, and WES.<xref ref-type="bibr" rid="JCTH-2025-00476-b33">33</xref> Commercial kits such as TaqMan assays and SmartAmp2 allow for rapid detection of single-nucleotide polymorphisms and specific variants of ABC transporters.<xref ref-type="bibr" rid="JCTH-2025-00476-b37">37</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b108">108</xref> Full gene sequencing may be used when clinical suspicion for a pathologic variant is high but targeted testing is negative. WES has shown superior sensitivity in detecting pathogenic variants, particularly in non-coding or regulatory regions. By incorporating family history and biochemical markers, genetic testing can further enhance diagnosis and inform treatment options. Multigene panel testing or whole-genome testing can be used to screen and identify key genes such as ATP8B1, <italic toggle="yes">ABCB11</italic>, and <italic toggle="yes">ABCB4</italic>, among others.<xref ref-type="bibr" rid="JCTH-2025-00476-b109">109</xref> Chen <italic toggle="yes">et al</italic>. studied three tiers of genetic analysis, including Sanger sequencing, panel-based NGS, and WES.<xref ref-type="bibr" rid="JCTH-2025-00476-b110">110</xref> WES had significantly higher diagnostic sensitivity and identified almost 32% of patients with pathogenic variants who were negative for mutations on NGS.</p><p>Consanguinity has been shown to increase the risk for ABC transporter-related disease. Cheema <italic toggle="yes">et al</italic>. studied genetic cholestatic disorders in 171 children and identified consanguinity in 88.1% of cases, with a family history of at least one affected sibling in nearly 65% of cases.<xref ref-type="bibr" rid="JCTH-2025-00476-b111">111</xref> Al-Hussaini <italic toggle="yes">et al</italic>. identified 65 patients, of whom 85% had consanguineous parents, with pathologic <italic toggle="yes">ATP8B1</italic> (n = 5), <italic toggle="yes">ABCB4</italic> (n = 25), or <italic toggle="yes">ABCB11</italic> (n = 35) gene mutations and early-onset cholestatic disease.<xref ref-type="bibr" rid="JCTH-2025-00476-b39">39</xref> Other cases have been reported with severe PFIC in homozygous <italic toggle="yes">ABCB4</italic> mutations in children born to consanguineous parents.<xref ref-type="bibr" rid="JCTH-2025-00476-b112">112</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b113">113</xref> Therefore, careful family histories can provide important indices of suspicion in cases of unexplained cholestasis. Xiao <italic toggle="yes">et al</italic>. performed large-scale population whole-exome and whole-genome sequencing on over 100,000 individuals across diverse ethnogeographic groups, suggesting that ABC transporter presentations may have population- and inter-ethnic genetic variability.<xref ref-type="bibr" rid="JCTH-2025-00476-b114">114</xref>
<italic toggle="yes">ABCB4</italic> and <italic toggle="yes">ABCB11</italic> gene mutations have not been studied in isolated communities such as Inuit or Amish groups, but there is evidence of a significantly increased presence of ABC transporter-related liver disease in ATP8B1 deficiency, likely due to “founder mutations,” which result in high-frequency genetic alterations from a small ancestral cohort.<xref ref-type="bibr" rid="JCTH-2025-00476-b115">115</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b116">116</xref> Other ABC transporter mutation variants have yet to be studied in these populations.</p><p>Because of evidence associating zygosity with severity of phenotype, genetic testing can provide important diagnostic and prognostic information and decrease the risk of biallelic offspring and severe disease through genetic counseling. It is recommended that diagnosis and genetic testing be done using a multidisciplinary approach, including genetic counseling to assist with family planning and provide the necessary psychosocial support.<xref ref-type="bibr" rid="JCTH-2025-00476-b117">117</xref></p></sec><sec id="s7"><title>Clinical implications and future directions</title><p>Pregnancy-associated hormone changes and exogenous use of progesterone have been associated with cholestatic disease in predisposed patients. Certain pharmacologic agents, including antibiotics and chemotherapy agents, among others, have been shown to inhibit transporter activity, triggering symptoms.</p><p>Consanguinity and the founder effect have a significant impact on the incidence and severity of ABC transporter-associated cholestasis, as 85%–90% of affected individuals have parental consanguinity.</p><p>UDCA and rifampicin may provide symptomatic relief in mild disease presentations, but surgical interventions, including partial biliary diversion and liver transplant, may be needed in refractory or severe progressive disease.</p><p>Pediatric patients and those with delayed presentations of clinical cholestasis of undetermined etiology, or a family history of cholestatic disease, should be considered for NGS or WES genetic testing. Genetic counseling should be considered, particularly in consanguineous populations where homozygous or compound heterozygous mutations are more prevalent.</p><p>Cell culture and animal models have provided fundamental insight into ABC transporter–mediated hepatic disease mechanisms as well as potential novel therapies. The latter include targeted therapeutic interventions with FXR agonists<xref ref-type="bibr" rid="JCTH-2025-00476-b118">118</xref> and PPAR ligands. Wagner <italic toggle="yes">et al</italic>. studied common bile duct–ligated wild-type (FXR +/+) and FXR knockout (FXR -/-) mice and observed preservation of <italic toggle="yes">ABCB11</italic> expression in wild-type mice but undetectable BSEP expression in knockout mice, suggesting BSEP dependence on FXR in mouse models.<xref ref-type="bibr" rid="JCTH-2025-00476-b119">119</xref> Ogata <italic toggle="yes">et al</italic>. treated human THP-1 macrophage cells, human WI38 fibroblast cells, and mouse fibroblast cells with PPAR agonists such as fenofibrate, bezafibrate, and gemfibrozil, and observed increased <italic toggle="yes">ABCA1</italic> mRNA and protein levels. The effects of fenofibrate and PPAR ligand <ext-link ext-link-type="pmc:entrez-nucleotide" xlink:href="LY518674" xmlns:xlink="http://www.w3.org/1999/xlink">LY518674</ext-link> on ABCA biogenesis decreased in the absence of PPARα, as studied in mouse fibroblasts.<xref ref-type="bibr" rid="JCTH-2025-00476-b120">120</xref></p><p>Gene-editing and adeno-associated viral (AAV)–mediated gene replacement techniques have been studied to restore <italic toggle="yes">ABCB11</italic> and <italic toggle="yes">ABCB4</italic> transporter function.<xref ref-type="bibr" rid="JCTH-2025-00476-b121">121</xref>,<xref ref-type="bibr" rid="JCTH-2025-00476-b122">122</xref> Aronson <italic toggle="yes">et al</italic>. administered AAV serotype 8-mediated gene therapy, derived by cloning hABCB4 cDNA into a modified AAV expression cassette, as a single dose to <italic toggle="yes">ABCB4</italic> knockout mice and found restoration of biliary phospholipid excretion with normalization of plasma alkaline phosphatase and bilirubin.<xref ref-type="bibr" rid="JCTH-2025-00476-b123">123</xref></p><p>Patient-derived hepatocyte and cholangiocyte models have also been studied and have shown the ability to use induced pluripotent stem cell-derived cells to study variant-specific targeted drug responses.<xref ref-type="bibr" rid="JCTH-2025-00476-b124">124</xref> Induced pluripotent stem cells were prepared from BSEP-deficient patients (<italic toggle="yes">ABCB11</italic> mutation) and differentiated into hepatocyte-like cells. Imagawa <italic toggle="yes">et al</italic>. utilized 4-phenylbutyrate (a potential PFIC2 treatment) in BSEP-deficient hepatocyte-like cells and found that the level of BSEP expression and the calculated biliary excretion index were preserved.<xref ref-type="bibr" rid="JCTH-2025-00476-b125">125</xref></p><p>Future research should be directed toward translating animal model findings into early-phase human trials to target and individualize the management of ABC transporter-associated cholestatic disease.</p></sec><sec id="s8"><title>Conclusions</title><p>ABC transporters are vital for bile acid, phospholipid, cholesterol, and bilirubin excretion and can be involved in the export of toxins associated with pharmacotherapies. ABC transporter mutations are underrecognized causes of inherited hepatobiliary diseases that present as a spectrum of cholestatic disorders ranging from benign episodic cholestasis to progressive liver failure. <italic toggle="yes">ABCB11</italic>, <italic toggle="yes">ABCB4</italic>, <italic toggle="yes">ABCC2</italic>, and <italic toggle="yes">ABCG5</italic>/8 gene mutations can result in benign cholestatic syndromes such as BRIC, ICP, and DJS, or severe disease such as PFIC and sitosterolemia. Disease severity seems to be strongly influenced by zygosity, mutation type, and environmental triggers. Homozygous and compound heterozygous mutations, particularly in <italic toggle="yes">ABCB11</italic> and <italic toggle="yes">ABCB4</italic> genes, are associated with early-onset, severe, and progressive cholestatic disease. In contrast, heterozygous variants typically result in milder disease, such as ICP and LPAC.</p></sec></body><back><ack><title>Acknowledgments</title><p>This work was made possible by the Herman Lopata Chair in Hepatitis Research.</p></ack><ref-list><title>References</title><ref id="JCTH-2025-00476-b1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moore</surname><given-names>JM</given-names></name><name name-style="western"><surname>Bell</surname><given-names>EL</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>RO</given-names></name><name name-style="western"><surname>Garfield</surname><given-names>AS</given-names></name></person-group><article-title>ABC transporters: human disease and pharmacotherapeutic potential</article-title><source>Trends Mol Med</source><year>2023</year><volume>29</volume><issue>2</issue><fpage>152</fpage><lpage>172</lpage><pub-id pub-id-type="doi">10.1016/j.molmed.2022.11.001</pub-id><pub-id pub-id-type="pmid">36503994</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vasiliou</surname><given-names>V</given-names></name><name name-style="western"><surname>Vasiliou</surname><given-names>K</given-names></name><name name-style="western"><surname>Nebert</surname><given-names>DW</given-names></name></person-group><article-title>Human ATP-binding cassette (ABC) transporter family</article-title><source>Hum Genomics</source><year>2009</year><volume>3</volume><issue>3</issue><fpage>281</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1186/1479-7364-3-3-281</pub-id><pub-id pub-id-type="pmid">19403462</pub-id><pub-id pub-id-type="pmcid">PMC2752038</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JE</given-names></name><name name-style="western"><surname>Choe</surname><given-names>BH</given-names></name><name name-style="western"><surname>Seo</surname><given-names>AN</given-names></name><name name-style="western"><surname>Bae</surname><given-names>HI</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>SK</given-names></name></person-group><article-title>Early Diagnosis of ABCB11 Spectrum Liver Disorders by Next Generation Sequencing</article-title><source>Pediatr Gastroenterol Hepatol Nutr</source><year>2017</year><volume>20</volume><issue>2</issue><fpage>114</fpage><lpage>123</lpage><pub-id pub-id-type="doi">10.5223/pghn.2017.20.2.114</pub-id><pub-id pub-id-type="pmid">28730136</pub-id><pub-id pub-id-type="pmcid">PMC5517378</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>XK</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>JJ</given-names></name></person-group><article-title>Clinical characteristics and ABCC2 genotype in Dubin-Johnson syndrome: A case report and review of the literature</article-title><source>World J Clin Cases</source><year>2021</year><volume>9</volume><issue>4</issue><fpage>878</fpage><lpage>885</lpage><pub-id pub-id-type="doi">10.12998/wjcc.v9.i4.878</pub-id><pub-id pub-id-type="pmid">33585635</pub-id><pub-id pub-id-type="pmcid">PMC7852649</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b5"><label>5</label><element-citation publication-type="webpage"><comment>Bravo:Gene. [Cited on October 20, 2025]. Available from: <ext-link ext-link-type="uri" xlink:href="https://bravo.sph.umich.edu/gene.html?id=ABCB11" xmlns:xlink="http://www.w3.org/1999/xlink">https://bravo.sph.umich.edu/gene.html?id=ABCB11</ext-link></comment></element-citation></ref><ref id="JCTH-2025-00476-b6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stieger</surname><given-names>B</given-names></name><name name-style="western"><surname>Meier</surname><given-names>Y</given-names></name><name name-style="western"><surname>Meier</surname><given-names>PJ</given-names></name></person-group><article-title>The bile salt export pump</article-title><source>Pflugers Arch</source><year>2007</year><volume>453</volume><issue>5</issue><fpage>611</fpage><lpage>620</lpage><pub-id pub-id-type="doi">10.1007/s00424-006-0152-8</pub-id><pub-id pub-id-type="pmid">17051391</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Uchiumi</surname><given-names>T</given-names></name><name name-style="western"><surname>Tanamachi</surname><given-names>H</given-names></name><name name-style="western"><surname>Kuchiwaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Kajita</surname><given-names>M</given-names></name><name name-style="western"><surname>Matsumoto</surname><given-names>S</given-names></name><name name-style="western"><surname>Yagi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Mutation and functional analysis of ABCC2/multidrug resistance protein 2 in a Japanese patient with Dubin-Johnson syndrome</article-title><source>Hepatol Res</source><year>2013</year><volume>43</volume><issue>5</issue><fpage>569</fpage><lpage>575</lpage><pub-id pub-id-type="doi">10.1111/j.1872-034X.2012.01103.x</pub-id><pub-id pub-id-type="pmid">23045960</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kartenbeck</surname><given-names>J</given-names></name><name name-style="western"><surname>Leuschner</surname><given-names>U</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>R</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>D</given-names></name></person-group><article-title>Absence of the canalicular isoform of the MRP gene-encoded conjugate export pump from the hepatocytes in Dubin-Johnson syndrome</article-title><source>Hepatology</source><year>1996</year><volume>23</volume><issue>5</issue><fpage>1061</fpage><lpage>1066</lpage><pub-id pub-id-type="doi">10.1053/jhep.1996.v23.pm0008621134</pub-id><pub-id pub-id-type="pmid">8621134</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Knisely</surname><given-names>AS</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>SS</given-names></name><name name-style="western"><surname>Meier</surname><given-names>Y</given-names></name><name name-style="western"><surname>Stieger</surname><given-names>B</given-names></name><name name-style="western"><surname>Byrne</surname><given-names>JA</given-names></name><name name-style="western"><surname>Portmann</surname><given-names>BC</given-names></name><etal/></person-group><article-title>Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency</article-title><source>Hepatology</source><year>2006</year><volume>44</volume><issue>2</issue><fpage>478</fpage><lpage>486</lpage><pub-id pub-id-type="doi">10.1002/hep.21287</pub-id><pub-id pub-id-type="pmid">16871584</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>F</given-names></name><name name-style="western"><surname>Patterson</surname><given-names>AD</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Krausz</surname><given-names>KW</given-names></name><name name-style="western"><surname>Neale</surname><given-names>G</given-names></name><etal/></person-group><article-title>Abcb11 deficiency induces cholestasis coupled to impaired β-fatty acid oxidation in mice</article-title><source>J Biol Chem</source><year>2012</year><volume>287</volume><issue>29</issue><fpage>24784</fpage><lpage>24794</lpage><pub-id pub-id-type="doi">10.1074/jbc.M111.329318</pub-id><pub-id pub-id-type="pmid">22619174</pub-id><pub-id pub-id-type="pmcid">PMC3397905</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sticova</surname><given-names>E</given-names></name><name name-style="western"><surname>Jirsa</surname><given-names>M</given-names></name></person-group><article-title>ABCB4 disease: Many faces of one gene deficiency</article-title><source>Ann Hepatol</source><year>2020</year><volume>19</volume><issue>2</issue><fpage>126</fpage><lpage>133</lpage><pub-id pub-id-type="doi">10.1016/j.aohep.2019.09.010</pub-id><pub-id pub-id-type="pmid">31759867</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Erlinger</surname><given-names>S</given-names></name></person-group><article-title>Low phospholipid-associated cholestasis and cholelithiasis</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2012</year><volume>36</volume><issue>Suppl 1</issue><fpage>S36</fpage><lpage>S40</lpage><pub-id pub-id-type="doi">10.1016/S2210-7401(12)70019-0</pub-id><pub-id pub-id-type="pmid">23141892</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Avena</surname><given-names>A</given-names></name><name name-style="western"><surname>Puggelli</surname><given-names>S</given-names></name><name name-style="western"><surname>Morris</surname><given-names>M</given-names></name><name name-style="western"><surname>Cerny</surname><given-names>A</given-names></name><name name-style="western"><surname>Andrade</surname><given-names>AR</given-names></name><name name-style="western"><surname>Pareti</surname><given-names>E</given-names></name><etal/></person-group><article-title>ABCB4 variants in adult patients with cholestatic disease are frequent and underdiagnosed</article-title><source>Dig Liver Dis</source><year>2021</year><volume>53</volume><issue>3</issue><fpage>329</fpage><lpage>344</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2020.12.003</pub-id><pub-id pub-id-type="pmid">33390354</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cao</surname><given-names>L</given-names></name><name name-style="western"><surname>Ling</surname><given-names>X</given-names></name><name name-style="western"><surname>Yan</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name><name name-style="western"><surname>Dong</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>Z</given-names></name><etal/></person-group><article-title>Clinical and genetic study of ABCB4 gene-related cholestatic liver disease in China: children and adults</article-title><source>Orphanet J Rare Dis</source><year>2024</year><volume>19</volume><issue>1</issue><fpage>157</fpage><pub-id pub-id-type="doi">10.1186/s13023-024-03179-w</pub-id><pub-id pub-id-type="pmid">38610052</pub-id><pub-id pub-id-type="pmcid">PMC11010299</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b15"><label>15</label><element-citation publication-type="webpage"><comment>Bravo Gene. [Cited on November 3, 2025]. Available from: <ext-link ext-link-type="uri" xlink:href="https://bravo.sph.umich.edu/gene.html?id=ABCB4" xmlns:xlink="http://www.w3.org/1999/xlink">https://bravo.sph.umich.edu/gene.html?id=ABCB4</ext-link></comment></element-citation></ref><ref id="JCTH-2025-00476-b16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goubault</surname><given-names>P</given-names></name><name name-style="western"><surname>Brunel</surname><given-names>T</given-names></name><name name-style="western"><surname>Rode</surname><given-names>A</given-names></name><name name-style="western"><surname>Bancel</surname><given-names>B</given-names></name><name name-style="western"><surname>Mohkam</surname><given-names>K</given-names></name><name name-style="western"><surname>Mabrut</surname><given-names>JY</given-names></name></person-group><article-title>Low-Phospholipid Associated Cholelithiasis (LPAC) syndrome: A synthetic review</article-title><source>J Visc Surg</source><year>2019</year><volume>156</volume><issue>4</issue><fpage>319</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/j.jviscsurg.2019.02.006</pub-id><pub-id pub-id-type="pmid">30922600</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Alam</surname><given-names>S</given-names></name><name name-style="western"><surname>Lal</surname><given-names>BB</given-names></name></person-group><article-title>Recent updates on progressive familial intrahepatic cholestasis types 1, 2 and 3: Outcome and therapeutic strategies</article-title><source>World J Hepatol</source><year>2022</year><volume>14</volume><issue>1</issue><fpage>98</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.4254/wjh.v14.i1.98</pub-id><pub-id pub-id-type="pmid">35126842</pub-id><pub-id pub-id-type="pmcid">PMC8790387</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Colombo</surname><given-names>C</given-names></name><name name-style="western"><surname>Vajro</surname><given-names>P</given-names></name><name name-style="western"><surname>Degiorgio</surname><given-names>D</given-names></name><name name-style="western"><surname>Coviello</surname><given-names>DA</given-names></name><name name-style="western"><surname>Costantino</surname><given-names>L</given-names></name><name name-style="western"><surname>Tornillo</surname><given-names>L</given-names></name><etal/></person-group><article-title>Clinical features and genotype-phenotype correlations in children with progressive familial intrahepatic cholestasis type 3 related to ABCB4 mutations</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2011</year><volume>52</volume><issue>1</issue><fpage>73</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3181f50363</pub-id><pub-id pub-id-type="pmid">21119540</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>X</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>X</given-names></name><name name-style="western"><surname>Chang</surname><given-names>XY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>J</given-names></name><etal/></person-group><article-title>Expert Consensus on Pathological Diagnosis of Intrahepatic Cholangiocarcinoma (2022 version)</article-title><source>J Clin Transl Hepatol</source><year>2023</year><volume>11</volume><issue>7</issue><fpage>1553</fpage><lpage>1564</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2023.00118</pub-id><pub-id pub-id-type="pmid">38161496</pub-id><pub-id pub-id-type="pmcid">PMC10752808</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dröge</surname><given-names>C</given-names></name><name name-style="western"><surname>Bonus</surname><given-names>M</given-names></name><name name-style="western"><surname>Baumann</surname><given-names>U</given-names></name><name name-style="western"><surname>Klindt</surname><given-names>C</given-names></name><name name-style="western"><surname>Lainka</surname><given-names>E</given-names></name><name name-style="western"><surname>Kathemann</surname><given-names>S</given-names></name><etal/></person-group><article-title>Sequencing of FIC1, BSEP and MDR3 in a large cohort of patients with cholestasis revealed a high number of different genetic variants</article-title><source>J Hepatol</source><year>2017</year><volume>67</volume><issue>6</issue><fpage>1253</fpage><lpage>1264</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2017.07.004</pub-id><pub-id pub-id-type="pmid">28733223</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Degiorgio</surname><given-names>D</given-names></name><name name-style="western"><surname>Crosignani</surname><given-names>A</given-names></name><name name-style="western"><surname>Colombo</surname><given-names>C</given-names></name><name name-style="western"><surname>Bordo</surname><given-names>D</given-names></name><name name-style="western"><surname>Zuin</surname><given-names>M</given-names></name><name name-style="western"><surname>Vassallo</surname><given-names>E</given-names></name><etal/></person-group><article-title>ABCB4 mutations in adult patients with cholestatic liver disease: impact and phenotypic expression</article-title><source>J Gastroenterol</source><year>2016</year><volume>51</volume><issue>3</issue><fpage>271</fpage><lpage>280</lpage><pub-id pub-id-type="doi">10.1007/s00535-015-1110-z</pub-id><pub-id pub-id-type="pmid">26324191</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gatselis</surname><given-names>NK</given-names></name><name name-style="western"><surname>Zachou</surname><given-names>K</given-names></name><name name-style="western"><surname>Koukoulis</surname><given-names>GK</given-names></name><name name-style="western"><surname>Dalekos</surname><given-names>GN</given-names></name></person-group><article-title>Autoimmune hepatitis, one disease with many faces: etiopathogenetic, clinico-laboratory and histological characteristics</article-title><source>World J Gastroenterol</source><year>2015</year><volume>21</volume><issue>1</issue><fpage>60</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.3748/wjg.v21.i1.60</pub-id><pub-id pub-id-type="pmid">25574080</pub-id><pub-id pub-id-type="pmcid">PMC4284362</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schatz</surname><given-names>SB</given-names></name><name name-style="western"><surname>Jüngst</surname><given-names>C</given-names></name><name name-style="western"><surname>Keitel-Anselmo</surname><given-names>V</given-names></name><name name-style="western"><surname>Kubitz</surname><given-names>R</given-names></name><name name-style="western"><surname>Becker</surname><given-names>C</given-names></name><name name-style="western"><surname>Gerner</surname><given-names>P</given-names></name><etal/></person-group><article-title>Phenotypic spectrum and diagnostic pitfalls of ABCB4 deficiency depending on age of onset</article-title><source>Hepatol Commun</source><year>2018</year><volume>2</volume><issue>5</issue><fpage>504</fpage><lpage>514</lpage><pub-id pub-id-type="doi">10.1002/hep4.1149</pub-id><pub-id pub-id-type="pmid">29761167</pub-id><pub-id pub-id-type="pmcid">PMC5944585</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fong</surname><given-names>V</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SB</given-names></name></person-group><article-title>Recent advances in ABCG5 and ABCG8 variants</article-title><source>Curr Opin Lipidol</source><year>2021</year><volume>32</volume><issue>2</issue><fpage>117</fpage><lpage>122</lpage><pub-id pub-id-type="doi">10.1097/MOL.0000000000000734</pub-id><pub-id pub-id-type="pmid">33395105</pub-id><pub-id pub-id-type="pmcid">PMC8650851</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Klett</surname><given-names>EL</given-names></name><name name-style="western"><surname>Lee</surname><given-names>MH</given-names></name><name name-style="western"><surname>Adams</surname><given-names>DB</given-names></name><name name-style="western"><surname>Chavin</surname><given-names>KD</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SB</given-names></name></person-group><article-title>Localization of ABCG5 and ABCG8 proteins in human liver, gall bladder and intestine</article-title><source>BMC Gastroenterol</source><year>2004</year><volume>4</volume><fpage>21</fpage><pub-id pub-id-type="doi">10.1186/1471-230X-4-21</pub-id><pub-id pub-id-type="pmid">15383151</pub-id><pub-id pub-id-type="pmcid">PMC522813</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b26"><label>26</label><element-citation publication-type="webpage"><comment>Bravo Gene. [Cited on November 3, 2025]. Available from: <ext-link ext-link-type="uri" xlink:href="https://bravo.sph.umich.edu/gene.html?id=ABCG5" xmlns:xlink="http://www.w3.org/1999/xlink">https://bravo.sph.umich.edu/gene.html?id=ABCG5</ext-link></comment></element-citation></ref><ref id="JCTH-2025-00476-b27"><label>27</label><element-citation publication-type="webpage"><comment>Bravo Gene. [Cited on November 3, 2025]. Available from: <ext-link ext-link-type="uri" xlink:href="https://bravo.sph.umich.edu/gene.html?id=ABCG8" xmlns:xlink="http://www.w3.org/1999/xlink">https://bravo.sph.umich.edu/gene.html?id=ABCG8</ext-link></comment></element-citation></ref><ref id="JCTH-2025-00476-b28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zein</surname><given-names>AA</given-names></name><name name-style="western"><surname>Kaur</surname><given-names>R</given-names></name><name name-style="western"><surname>Hussein</surname><given-names>TOK</given-names></name><name name-style="western"><surname>Graf</surname><given-names>GA</given-names></name><name name-style="western"><surname>Lee</surname><given-names>JY</given-names></name></person-group><article-title>ABCG5/G8: a structural view to pathophysiology of the hepatobiliary cholesterol secretion</article-title><source>Biochem Soc Trans</source><year>2019</year><volume>47</volume><issue>5</issue><fpage>1259</fpage><lpage>1268</lpage><pub-id pub-id-type="doi">10.1042/BST20190130</pub-id><pub-id pub-id-type="pmid">31654053</pub-id><pub-id pub-id-type="pmcid">PMC6824678</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yu</surname><given-names>L</given-names></name><name name-style="western"><surname>Hammer</surname><given-names>RE</given-names></name><name name-style="western"><surname>Li-Hawkins</surname><given-names>J</given-names></name><name name-style="western"><surname>Von Bergmann</surname><given-names>K</given-names></name><name name-style="western"><surname>Lutjohann</surname><given-names>D</given-names></name><name name-style="western"><surname>Cohen</surname><given-names>JC</given-names></name><etal/></person-group><article-title>Disruption of Abcg5 and Abcg8 in mice reveals their crucial role in biliary cholesterol secretion</article-title><source>Proc Natl Acad Sci U S A</source><year>2002</year><volume>99</volume><issue>25</issue><fpage>16237</fpage><lpage>42</lpage><pub-id pub-id-type="doi">10.1073/pnas.252582399</pub-id><pub-id pub-id-type="pmid">12444248</pub-id><pub-id pub-id-type="pmcid">PMC138595</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nies</surname><given-names>AT</given-names></name><name name-style="western"><surname>Keppler</surname><given-names>D</given-names></name></person-group><article-title>The apical conjugate efflux pump ABCC2 (MRP2)</article-title><source>Pflugers Arch</source><year>2007</year><volume>453</volume><issue>5</issue><fpage>643</fpage><lpage>659</lpage><pub-id pub-id-type="doi">10.1007/s00424-006-0109-y</pub-id><pub-id pub-id-type="pmid">16847695</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b31"><label>31</label><element-citation publication-type="webpage"><comment>Bravo Gene. [Cited on November 3, 2025]. Available from: <ext-link ext-link-type="uri" xlink:href="https://bravo.sph.umich.edu/gene.html?id=ABCC2" xmlns:xlink="http://www.w3.org/1999/xlink">https://bravo.sph.umich.edu/gene.html?id=ABCC2</ext-link></comment></element-citation></ref><ref id="JCTH-2025-00476-b32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dixon</surname><given-names>PH</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>C</given-names></name></person-group><article-title>The molecular genetics of intrahepatic cholestasis of pregnancy</article-title><source>Obstet Med</source><year>2008</year><volume>1</volume><issue>2</issue><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="doi">10.1258/om.2008.080010</pub-id><pub-id pub-id-type="pmid">27582788</pub-id><pub-id pub-id-type="pmcid">PMC4989713</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stättermayer</surname><given-names>AF</given-names></name><name name-style="western"><surname>Halilbasic</surname><given-names>E</given-names></name><name name-style="western"><surname>Wrba</surname><given-names>F</given-names></name><name name-style="western"><surname>Ferenci</surname><given-names>P</given-names></name><name name-style="western"><surname>Trauner</surname><given-names>M</given-names></name></person-group><article-title>Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults</article-title><source>J Hepatol</source><year>2020</year><volume>73</volume><issue>3</issue><fpage>651</fpage><lpage>663</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2020.04.036</pub-id><pub-id pub-id-type="pmid">32376413</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Hayashi</surname><given-names>H</given-names></name><name name-style="western"><surname>Sabu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tanikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Fujishiro</surname><given-names>J</given-names></name><name name-style="western"><surname>Kajikawa</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical phenotype and molecular analysis of a homozygous ABCB11 mutation responsible for progressive infantile cholestasis</article-title><source>J Hum Genet</source><year>2018</year><volume>63</volume><issue>5</issue><fpage>569</fpage><lpage>577</lpage><pub-id pub-id-type="doi">10.1038/s10038-018-0431-1</pub-id><pub-id pub-id-type="pmid">29507376</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gordo-Gilart</surname><given-names>R</given-names></name><name name-style="western"><surname>Hierro</surname><given-names>L</given-names></name><name name-style="western"><surname>Andueza</surname><given-names>S</given-names></name><name name-style="western"><surname>Muñoz-Bartolo</surname><given-names>G</given-names></name><name name-style="western"><surname>López</surname><given-names>C</given-names></name><name name-style="western"><surname>Díaz</surname><given-names>C</given-names></name><etal/></person-group><article-title>Heterozygous ABCB4 mutations in children with cholestatic liver disease</article-title><source>Liver Int</source><year>2016</year><volume>36</volume><issue>2</issue><fpage>258</fpage><lpage>267</lpage><pub-id pub-id-type="doi">10.1111/liv.12910</pub-id><pub-id pub-id-type="pmid">26153658</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Saleem</surname><given-names>K</given-names></name><name name-style="western"><surname>Cui</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zaib</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>S</given-names></name><name name-style="western"><surname>Qin</surname><given-names>Q</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Evaluation of a Novel Missense Mutation in ABCB4 Gene Causing Progressive Familial Intrahepatic Cholestasis Type 3</article-title><source>Dis Markers</source><year>2020</year><volume>2020</volume><fpage>6292818</fpage><pub-id pub-id-type="doi">10.1155/2020/6292818</pub-id><pub-id pub-id-type="pmid">32626542</pub-id><pub-id pub-id-type="pmcid">PMC7315263</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jüngst</surname><given-names>C</given-names></name><name name-style="western"><surname>Justinger</surname><given-names>C</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>J</given-names></name><name name-style="western"><surname>Berg</surname><given-names>T</given-names></name><name name-style="western"><surname>Lammert</surname><given-names>F</given-names></name></person-group><article-title>Common ABCB4 and ABCB11 Genotypes Are Associated with Idiopathic Chronic Cholestasis in Adults</article-title><source>Dig Dis</source><year>2022</year><volume>40</volume><issue>4</issue><fpage>489</fpage><lpage>496</lpage><pub-id pub-id-type="doi">10.1159/000518203</pub-id><pub-id pub-id-type="pmid">34348275</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hegarty</surname><given-names>R</given-names></name><name name-style="western"><surname>Gurra</surname><given-names>O</given-names></name><name name-style="western"><surname>Tarawally</surname><given-names>J</given-names></name><name name-style="western"><surname>Allouni</surname><given-names>S</given-names></name><name name-style="western"><surname>Rahman</surname><given-names>O</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>S</given-names></name><etal/></person-group><article-title>Clinical outcomes of ABCB4 heterozygosity in infants and children with cholestatic liver disease</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2024</year><volume>78</volume><issue>2</issue><fpage>339</fpage><lpage>349</lpage><pub-id pub-id-type="doi">10.1002/jpn3.12080</pub-id><pub-id pub-id-type="pmid">38374565</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al-Hussaini</surname><given-names>A</given-names></name><name name-style="western"><surname>Lone</surname><given-names>K</given-names></name><name name-style="western"><surname>Bashir</surname><given-names>MS</given-names></name><name name-style="western"><surname>Alrashidi</surname><given-names>S</given-names></name><name name-style="western"><surname>Fagih</surname><given-names>M</given-names></name><name name-style="western"><surname>Alanazi</surname><given-names>A</given-names></name><etal/></person-group><article-title>ATP8B1, ABCB11, and ABCB4 Genes Defects: Novel Mutations Associated with Cholestasis with Different Phenotypes and Outcomes</article-title><source>J Pediatr</source><year>2021</year><volume>236</volume><fpage>113</fpage><lpage>123.e2</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2021.04.040</pub-id><pub-id pub-id-type="pmid">33915153</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>H</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>B</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>Y</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Gu</surname><given-names>HM</given-names></name><name name-style="western"><surname>Imran</surname><given-names>M</given-names></name><etal/></person-group><article-title>The spectrum of novel ABCB11 gene variations in children with progressive familial intrahepatic cholestasis type 2 in Pakistani cohorts</article-title><source>Sci Rep</source><year>2024</year><volume>14</volume><issue>1</issue><fpage>18876</fpage><pub-id pub-id-type="doi">10.1038/s41598-024-59945-0</pub-id><pub-id pub-id-type="pmid">39143102</pub-id><pub-id pub-id-type="pmcid">PMC11324741</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baker</surname><given-names>A</given-names></name><name name-style="western"><surname>Kerkar</surname><given-names>N</given-names></name><name name-style="western"><surname>Todorova</surname><given-names>L</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>BM</given-names></name><name name-style="western"><surname>Houwen</surname><given-names>RHJ</given-names></name></person-group><article-title>Systematic review of progressive familial intrahepatic cholestasis</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2019</year><volume>43</volume><issue>1</issue><fpage>20</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.clinre.2018.07.010</pub-id><pub-id pub-id-type="pmid">30236549</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>LY</given-names></name><name name-style="western"><surname>Wang</surname><given-names>ZL</given-names></name><name name-style="western"><surname>Wang</surname><given-names>XH</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>QR</given-names></name><name name-style="western"><surname>Wang</surname><given-names>JS</given-names></name></person-group><article-title>ABCB11 gene mutations in Chinese children with progressive intrahepatic cholestasis and low gamma glutamyltransferase</article-title><source>Liver Int</source><year>2010</year><volume>30</volume><issue>6</issue><fpage>809</fpage><lpage>815</lpage><pub-id pub-id-type="doi">10.1111/j.1478-3231.2009.02112.x</pub-id><pub-id pub-id-type="pmid">19845854</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>HL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>YJ</given-names></name><name name-style="western"><surname>Su</surname><given-names>YN</given-names></name><name name-style="western"><surname>Wang</surname><given-names>NY</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SH</given-names></name><name name-style="western"><surname>Ni</surname><given-names>YH</given-names></name><etal/></person-group><article-title>Diagnosis of BSEP/ABCB11 mutations in Asian patients with cholestasis using denaturing high performance liquid chromatography</article-title><source>J Pediatr</source><year>2008</year><volume>153</volume><issue>6</issue><fpage>825</fpage><lpage>832</lpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2008.06.034</pub-id><pub-id pub-id-type="pmid">18692205</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>XX</given-names></name><name name-style="western"><surname>Ye</surname><given-names>MY</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>JY</given-names></name><name name-style="western"><surname>Li</surname><given-names>L</given-names></name><name name-style="western"><surname>Chen</surname><given-names>W</given-names></name><etal/></person-group><article-title>Prevalence and risk factors of intrahepatic cholestasis of pregnancy in a Chinese population</article-title><source>Sci Rep</source><year>2020</year><volume>10</volume><issue>1</issue><fpage>16307</fpage><pub-id pub-id-type="doi">10.1038/s41598-020-73378-5</pub-id><pub-id pub-id-type="pmid">33004915</pub-id><pub-id pub-id-type="pmcid">PMC7530728</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran</surname><given-names>TT</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J</given-names></name><name name-style="western"><surname>Reau</surname><given-names>NS</given-names></name></person-group><article-title>ACG Clinical Guideline: Liver Disease and Pregnancy</article-title><source>Am J Gastroenterol</source><year>2016</year><volume>111</volume><issue>2</issue><fpage>176</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1038/ajg.2015.430</pub-id><pub-id pub-id-type="pmid">26832651</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Odutola</surname><given-names>PO</given-names></name><name name-style="western"><surname>Olorunyomi</surname><given-names>PO</given-names></name><name name-style="western"><surname>Olatawura</surname><given-names>OO</given-names></name><name name-style="western"><surname>Olorunyomi</surname><given-names>I</given-names></name><name name-style="western"><surname>Madojutimi</surname><given-names>O</given-names></name><name name-style="western"><surname>Fatunsin</surname><given-names>AO</given-names></name><etal/></person-group><article-title>Intrahepatic cholestasis of pregnancy is associated with increased risk of hepatobiliary disease and adverse fetal outcomes: A systematic review and meta-analysis</article-title><source>ILIVER</source><year>2023</year><volume>2</volume><issue>4</issue><fpage>219</fpage><lpage>226</lpage><pub-id pub-id-type="doi">10.1016/j.iliver.2023.11.001</pub-id><pub-id pub-id-type="pmid">40636920</pub-id><pub-id pub-id-type="pmcid">PMC12212689</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lammert</surname><given-names>F</given-names></name><name name-style="western"><surname>Marschall</surname><given-names>HU</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>A</given-names></name><name name-style="western"><surname>Matern</surname><given-names>S</given-names></name></person-group><article-title>Intrahepatic cholestasis of pregnancy: molecular pathogenesis, diagnosis and management</article-title><source>J Hepatol</source><year>2000</year><volume>33</volume><issue>6</issue><fpage>1012</fpage><lpage>1021</lpage><pub-id pub-id-type="doi">10.1016/s0168-8278(00)80139-7</pub-id><pub-id pub-id-type="pmid">11131439</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rioseco</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ivankovic</surname><given-names>MB</given-names></name><name name-style="western"><surname>Manzur</surname><given-names>A</given-names></name><name name-style="western"><surname>Hamed</surname><given-names>F</given-names></name><name name-style="western"><surname>Kato</surname><given-names>SR</given-names></name><name name-style="western"><surname>Parer</surname><given-names>JT</given-names></name><etal/></person-group><article-title>Intrahepatic cholestasis of pregnancy: a retrospective case-control study of perinatal outcome</article-title><source>Am J Obstet Gynecol</source><year>1994</year><volume>170</volume><issue>3</issue><fpage>890</fpage><lpage>895</lpage><pub-id pub-id-type="doi">10.1016/s0002-9378(94)70304-3</pub-id><pub-id pub-id-type="pmid">8141222</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b49"><label>49</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Pillarisetty</surname><given-names>LS</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>A</given-names></name></person-group><article-title>Pregnancy Intrahepatic Cholestasis</article-title><source>StatPearls</source><year>2025</year><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="JCTH-2025-00476-b50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wasmuth</surname><given-names>HE</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>A</given-names></name><name name-style="western"><surname>Keppeler</surname><given-names>H</given-names></name><name name-style="western"><surname>Simon</surname><given-names>E</given-names></name><name name-style="western"><surname>Bartz</surname><given-names>C</given-names></name><name name-style="western"><surname>Rath</surname><given-names>W</given-names></name><etal/></person-group><article-title>Intrahepatic cholestasis of pregnancy: the severe form is associated with common variants of the hepatobiliary phospholipid transporter ABCB4 gene</article-title><source>Gut</source><year>2007</year><volume>56</volume><issue>2</issue><fpage>265</fpage><lpage>270</lpage><pub-id pub-id-type="doi">10.1136/gut.2006.092742</pub-id><pub-id pub-id-type="pmid">16891356</pub-id><pub-id pub-id-type="pmcid">PMC1856745</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fisk</surname><given-names>NM</given-names></name><name name-style="western"><surname>Storey</surname><given-names>GN</given-names></name></person-group><article-title>Fetal outcome in obstetric cholestasis</article-title><source>Br J Obstet Gynaecol</source><year>1988</year><volume>95</volume><issue>11</issue><fpage>1137</fpage><lpage>1143</lpage><pub-id pub-id-type="doi">10.1111/j.1471-0528.1988.tb06791.x</pub-id><pub-id pub-id-type="pmid">3207643</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geenes</surname><given-names>V</given-names></name><name name-style="western"><surname>Chappell</surname><given-names>LC</given-names></name><name name-style="western"><surname>Seed</surname><given-names>PT</given-names></name><name name-style="western"><surname>Steer</surname><given-names>PJ</given-names></name><name name-style="western"><surname>Knight</surname><given-names>M</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>C</given-names></name></person-group><article-title>Association of severe intrahepatic cholestasis of pregnancy with adverse pregnancy outcomes: a prospective population-based case-control study</article-title><source>Hepatology</source><year>2014</year><volume>59</volume><issue>4</issue><fpage>1482</fpage><lpage>1491</lpage><pub-id pub-id-type="doi">10.1002/hep.26617</pub-id><pub-id pub-id-type="pmid">23857305</pub-id><pub-id pub-id-type="pmcid">PMC4296226</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lee</surname><given-names>RH</given-names></name><name name-style="western"><surname>Kwok</surname><given-names>KM</given-names></name><name name-style="western"><surname>Ingles</surname><given-names>S</given-names></name><name name-style="western"><surname>Wilson</surname><given-names>ML</given-names></name><name name-style="western"><surname>Mullin</surname><given-names>P</given-names></name><name name-style="western"><surname>Incerpi</surname><given-names>M</given-names></name><etal/></person-group><article-title>Pregnancy outcomes during an era of aggressive management for intrahepatic cholestasis of pregnancy</article-title><source>Am J Perinatol</source><year>2008</year><volume>25</volume><issue>6</issue><fpage>341</fpage><lpage>345</lpage><pub-id pub-id-type="doi">10.1055/s-2008-1078756</pub-id><pub-id pub-id-type="pmid">18509787</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacq</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sentilhes</surname><given-names>L</given-names></name></person-group><article-title>Intrahepatic cholestasis of pregnancy: Diagnosis and management</article-title><source>Clin Liver Dis (Hoboken)</source><year>2014</year><volume>4</volume><issue>3</issue><fpage>58</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/cld.398</pub-id><pub-id pub-id-type="pmid">30992922</pub-id><pub-id pub-id-type="pmcid">PMC6448735</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kothari</surname><given-names>S</given-names></name><name name-style="western"><surname>Afshar</surname><given-names>Y</given-names></name><name name-style="western"><surname>Friedman</surname><given-names>LS</given-names></name><name name-style="western"><surname>Ahn</surname><given-names>J</given-names></name></person-group><article-title>AGA Clinical Practice Update on Pregnancy-Related Gastrointestinal and Liver Disease: Expert Review</article-title><source>Gastroenterology</source><year>2024</year><volume>167</volume><issue>5</issue><fpage>1033</fpage><lpage>1045</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2024.06.014</pub-id><pub-id pub-id-type="pmid">39140906</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacq</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sapey</surname><given-names>T</given-names></name><name name-style="western"><surname>Bréchot</surname><given-names>MC</given-names></name><name name-style="western"><surname>Pierre</surname><given-names>F</given-names></name><name name-style="western"><surname>Fignon</surname><given-names>A</given-names></name><name name-style="western"><surname>Dubois</surname><given-names>F</given-names></name></person-group><article-title>Intrahepatic cholestasis of pregnancy: a French prospective study</article-title><source>Hepatology</source><year>1997</year><volume>26</volume><issue>2</issue><fpage>358</fpage><lpage>364</lpage><pub-id pub-id-type="doi">10.1002/hep.510260216</pub-id><pub-id pub-id-type="pmid">9252146</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bacq</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sentilhes</surname><given-names>L</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>HB</given-names></name><name name-style="western"><surname>Glantz</surname><given-names>A</given-names></name><name name-style="western"><surname>Kondrackiene</surname><given-names>J</given-names></name><name name-style="western"><surname>Binder</surname><given-names>T</given-names></name><etal/></person-group><article-title>Efficacy of ursodeoxycholic acid in treating intrahepatic cholestasis of pregnancy: a meta-analysis</article-title><source>Gastroenterology</source><year>2012</year><volume>143</volume><issue>6</issue><fpage>1492</fpage><lpage>1501</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2012.08.004</pub-id><pub-id pub-id-type="pmid">22892336</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Davit-Spraul</surname><given-names>A</given-names></name><name name-style="western"><surname>Fabre</surname><given-names>M</given-names></name><name name-style="western"><surname>Branchereau</surname><given-names>S</given-names></name><name name-style="western"><surname>Baussan</surname><given-names>C</given-names></name><name name-style="western"><surname>Gonzales</surname><given-names>E</given-names></name><name name-style="western"><surname>Stieger</surname><given-names>B</given-names></name><etal/></person-group><article-title>ATP8B1 and ABCB11 analysis in 62 children with normal gamma-glutamyl transferase progressive familial intrahepatic cholestasis (PFIC): phenotypic differences between PFIC1 and PFIC2 and natural history</article-title><source>Hepatology</source><year>2010</year><volume>51</volume><issue>5</issue><fpage>1645</fpage><lpage>1655</lpage><pub-id pub-id-type="doi">10.1002/hep.23539</pub-id><pub-id pub-id-type="pmid">20232290</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Geladari</surname><given-names>EV</given-names></name><name name-style="western"><surname>Vallianou</surname><given-names>NG</given-names></name><name name-style="western"><surname>Margellou</surname><given-names>E</given-names></name><name name-style="western"><surname>Kounatidis</surname><given-names>D</given-names></name><name name-style="western"><surname>Sevastianos</surname><given-names>V</given-names></name><name name-style="western"><surname>Alexopoulou</surname><given-names>A</given-names></name></person-group><article-title>Benign Recurrent Intrahepatic Cholestasis: Where Are We Now?</article-title><source>Gastroenterol Insights</source><year>2024</year><volume>15</volume><issue>1</issue><fpage>156</fpage><lpage>167</lpage><pub-id pub-id-type="doi">10.3390/gastroent15010011</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Langedijk</surname><given-names>JAGM</given-names></name><name name-style="western"><surname>Beuers</surname><given-names>UH</given-names></name><name name-style="western"><surname>Oude Elferink</surname><given-names>RPJ</given-names></name></person-group><article-title>Cholestasis-Associated Pruritus and Its Pruritogens</article-title><source>Front Med (Lausanne)</source><year>2021</year><volume>8</volume><fpage>639674</fpage><pub-id pub-id-type="doi">10.3389/fmed.2021.639674</pub-id><pub-id pub-id-type="pmid">33791327</pub-id><pub-id pub-id-type="pmcid">PMC8006388</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b61"><label>61</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Riaz</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>P</given-names></name><name name-style="western"><surname>John</surname><given-names>S</given-names></name></person-group><article-title>Cholestyramine Resin</article-title><source>StatPearls</source><year>2025</year><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="JCTH-2025-00476-b62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kondrackiene</surname><given-names>J</given-names></name><name name-style="western"><surname>Beuers</surname><given-names>U</given-names></name><name name-style="western"><surname>Kupcinskas</surname><given-names>L</given-names></name></person-group><article-title>Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy</article-title><source>Gastroenterology</source><year>2005</year><volume>129</volume><issue>3</issue><fpage>894</fpage><lpage>901</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.06.019</pub-id><pub-id pub-id-type="pmid">16143129</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sohn</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Woo</surname><given-names>MH</given-names></name><name name-style="western"><surname>Seong</surname><given-names>MW</given-names></name><name name-style="western"><surname>Park</surname><given-names>SS</given-names></name><name name-style="western"><surname>Kang</surname><given-names>GH</given-names></name><name name-style="western"><surname>Moon</surname><given-names>JS</given-names></name><etal/></person-group><article-title>Benign Recurrent Intrahepatic Cholestasis Type 2 in Siblings with Novel ABCB11 Mutations</article-title><source>Pediatr Gastroenterol Hepatol Nutr</source><year>2019</year><volume>22</volume><issue>2</issue><fpage>201</fpage><lpage>206</lpage><pub-id pub-id-type="doi">10.5223/pghn.2019.22.2.201</pub-id><pub-id pub-id-type="pmid">30899697</pub-id><pub-id pub-id-type="pmcid">PMC6416387</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ermis</surname><given-names>F</given-names></name><name name-style="western"><surname>Oncu</surname><given-names>K</given-names></name><name name-style="western"><surname>Ozel</surname><given-names>M</given-names></name><name name-style="western"><surname>Yazgan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gurbuz</surname><given-names>AK</given-names></name><name name-style="western"><surname>Demirturk</surname><given-names>L</given-names></name><etal/></person-group><article-title>Benign recurrent intrahepatic cholestasis: late initial diagnosis in adulthood</article-title><source>Ann Hepatol</source><year>2010</year><volume>9</volume><issue>2</issue><fpage>207</fpage><lpage>210</lpage><pub-id pub-id-type="doi">10.1016/S1665-2681(19)31665-5</pub-id><pub-id pub-id-type="pmid">20526019</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Folvik</surname><given-names>G</given-names></name><name name-style="western"><surname>Hilde</surname><given-names>O</given-names></name><name name-style="western"><surname>Helge</surname><given-names>GO</given-names></name></person-group><article-title>Benign recurrent intrahepatic cholestasis: review and long-term follow-up of five cases</article-title><source>Scand J Gastroenterol</source><year>2012</year><volume>47</volume><issue>4</issue><fpage>482</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.3109/00365521.2011.650191</pub-id><pub-id pub-id-type="pmid">22229830</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luketic</surname><given-names>VA</given-names></name><name name-style="western"><surname>Shiffman</surname><given-names>ML</given-names></name></person-group><article-title>Benign recurrent intrahepatic cholestasis</article-title><source>Clin Liver Dis</source><year>2004</year><volume>8</volume><issue>1</issue><fpage>133</fpage><lpage>149</lpage><pub-id pub-id-type="doi">10.1016/S1089-3261(03)00133-8</pub-id><pub-id pub-id-type="pmid">15062197</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kumar</surname><given-names>M</given-names></name><name name-style="western"><surname>Singh</surname><given-names>K</given-names></name><name name-style="western"><surname>Singh</surname><given-names>KK</given-names></name></person-group><article-title>Understanding the Difference in Various Fractions of Serum Bilirubin while Estimated by Wet Chemistry and Dry Chemistry Method and its Importance in Neonatal Jaundice</article-title><source>Indian J Med Biochem</source><year>2023</year><volume>26</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><pub-id pub-id-type="doi">10.5005/jp-journals-10054-0200</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stapelbroek</surname><given-names>JM</given-names></name><name name-style="western"><surname>van Erpecum</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Klomp</surname><given-names>LW</given-names></name><name name-style="western"><surname>Houwen</surname><given-names>RH</given-names></name></person-group><article-title>Liver disease associated with canalicular transport defects: current and future therapies</article-title><source>J Hepatol</source><year>2010</year><volume>52</volume><issue>2</issue><fpage>258</fpage><lpage>271</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2009.11.012</pub-id><pub-id pub-id-type="pmid">20034695</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vij</surname><given-names>M</given-names></name><name name-style="western"><surname>Sankaranarayanan</surname><given-names>S</given-names></name></person-group><article-title>Biallelic Mutations in Ubiquitin-Specific Peptidase 53 (USP53) Causing Progressive Intrahepatic Cholestasis. Report of a Case With Review of Literature</article-title><source>Pediatr Dev Pathol</source><year>2022</year><volume>25</volume><issue>2</issue><fpage>207</fpage><lpage>212</lpage><pub-id pub-id-type="doi">10.1177/10935266211051175</pub-id><pub-id pub-id-type="pmid">34809518</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Muntaha</surname><given-names>HST</given-names></name><name name-style="western"><surname>Munir</surname><given-names>M</given-names></name><name name-style="western"><surname>Sajid</surname><given-names>SH</given-names></name><name name-style="western"><surname>Sarfraz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Sarfraz</surname><given-names>A</given-names></name><name name-style="western"><surname>Robles-Velasco</surname><given-names>K</given-names></name><etal/></person-group><article-title>Ileal Bile Acid Transporter Blockers for Cholestatic Liver Disease in Pediatric Patients with Alagille Syndrome: A Systematic Review and Meta-Analysis</article-title><source>J Clin Med</source><year>2022</year><volume>11</volume><issue>24</issue><fpage>7526</fpage><pub-id pub-id-type="doi">10.3390/jcm11247526</pub-id><pub-id pub-id-type="pmid">36556142</pub-id><pub-id pub-id-type="pmcid">PMC9784790</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>BM</given-names></name><name name-style="western"><surname>Stein</surname><given-names>P</given-names></name><name name-style="western"><surname>Houwen</surname><given-names>RHJ</given-names></name><name name-style="western"><surname>Verkade</surname><given-names>HJ</given-names></name></person-group><article-title>Potential of ileal bile acid transporter inhibition as a therapeutic target in Alagille syndrome and progressive familial intrahepatic cholestasis</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><issue>8</issue><fpage>1812</fpage><lpage>1822</lpage><pub-id pub-id-type="doi">10.1111/liv.14553</pub-id><pub-id pub-id-type="pmid">32492754</pub-id><pub-id pub-id-type="pmcid">PMC7496162</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></name></person-group><article-title>Progressive familial intrahepatic cholestasis</article-title><source>J Clin Exp Hepatol</source><year>2014</year><volume>4</volume><issue>1</issue><fpage>25</fpage><lpage>36</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2013.10.005</pub-id><pub-id pub-id-type="pmid">25755532</pub-id><pub-id pub-id-type="pmcid">PMC4017198</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nayagam</surname><given-names>JS</given-names></name><name name-style="western"><surname>Foskett</surname><given-names>P</given-names></name><name name-style="western"><surname>Strautnieks</surname><given-names>S</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>K</given-names></name><name name-style="western"><surname>Miquel</surname><given-names>R</given-names></name><name name-style="western"><surname>Joshi</surname><given-names>D</given-names></name><etal/></person-group><article-title>Clinical phenotype of adult-onset liver disease in patients with variants in ABCB4, ABCB11, and ATP8B1</article-title><source>Hepatol Commun</source><year>2022</year><volume>6</volume><issue>10</issue><fpage>2654</fpage><lpage>2664</lpage><pub-id pub-id-type="doi">10.1002/hep4.2051</pub-id><pub-id pub-id-type="pmid">35894240</pub-id><pub-id pub-id-type="pmcid">PMC9512461</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b74"><label>74</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>A Siddiqi</surname><given-names>I</given-names></name><name name-style="western"><surname>Tadi</surname><given-names>P</given-names></name></person-group><article-title>Progressive Familial Intrahepatic Cholestasis</article-title><source>StatPearls</source><year>2025</year><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="JCTH-2025-00476-b75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kamath</surname><given-names>BM</given-names></name><name name-style="western"><surname>Alonso</surname><given-names>EM</given-names></name><name name-style="western"><surname>Heubi</surname><given-names>JE</given-names></name><name name-style="western"><surname>Karpen</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Sundaram</surname><given-names>SS</given-names></name><name name-style="western"><surname>Shneider</surname><given-names>BL</given-names></name><etal/></person-group><article-title>Fat Soluble Vitamin Assessment and Supplementation in Cholestasis</article-title><source>Clin Liver Dis</source><year>2022</year><volume>26</volume><issue>3</issue><fpage>537</fpage><lpage>553</lpage><pub-id pub-id-type="doi">10.1016/j.cld.2022.03.011</pub-id><pub-id pub-id-type="pmid">35868689</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gaur</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakhuja</surname><given-names>P</given-names></name></person-group><article-title>Progressive familial intrahepatic cholestasis: A comprehensive review of a challenging liver disease</article-title><source>Indian J Pathol Microbiol</source><year>2017</year><volume>60</volume><issue>1</issue><fpage>2</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.4103/0377-4929.200040</pub-id><pub-id pub-id-type="pmid">28195083</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jankowska</surname><given-names>I</given-names></name><name name-style="western"><surname>Czubkowski</surname><given-names>P</given-names></name><name name-style="western"><surname>Kaliciński</surname><given-names>P</given-names></name><name name-style="western"><surname>Ismail</surname><given-names>H</given-names></name><name name-style="western"><surname>Kowalski</surname><given-names>A</given-names></name><name name-style="western"><surname>Ryżko</surname><given-names>J</given-names></name><etal/></person-group><article-title>Ileal exclusion in children with progressive familial intrahepatic cholestasis</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2014</year><volume>58</volume><issue>1</issue><fpage>92</fpage><lpage>95</lpage><pub-id pub-id-type="doi">10.1097/MPG.0b013e3182a9097c</pub-id><pub-id pub-id-type="pmid">24385022</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosmorduc</surname><given-names>O</given-names></name><name name-style="western"><surname>Hermelin</surname><given-names>B</given-names></name><name name-style="western"><surname>Boelle</surname><given-names>PY</given-names></name><name name-style="western"><surname>Parc</surname><given-names>R</given-names></name><name name-style="western"><surname>Taboury</surname><given-names>J</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>R</given-names></name></person-group><article-title>ABCB4 gene mutation-associated cholelithiasis in adults</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><issue>2</issue><fpage>452</fpage><lpage>459</lpage><pub-id pub-id-type="doi">10.1016/s0016-5085(03)00898-9</pub-id><pub-id pub-id-type="pmid">12891548</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dong</surname><given-names>C</given-names></name><name name-style="western"><surname>Condat</surname><given-names>B</given-names></name><name name-style="western"><surname>Picon-Coste</surname><given-names>M</given-names></name><name name-style="western"><surname>Chrétien</surname><given-names>Y</given-names></name><name name-style="western"><surname>Potier</surname><given-names>P</given-names></name><name name-style="western"><surname>Noblinski</surname><given-names>B</given-names></name><etal/></person-group><article-title>Low-phospholipid-associated cholelithiasis syndrome: Prevalence, clinical features, and comorbidities</article-title><source>JHEP Rep</source><year>2021</year><volume>3</volume><issue>2</issue><fpage>100201</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2020.100201</pub-id><pub-id pub-id-type="pmid">33554096</pub-id><pub-id pub-id-type="pmcid">PMC7848766</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosmorduc</surname><given-names>O</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>R</given-names></name></person-group><article-title>Low phospholipid associated cholelithiasis: association with mutation in the MDR3/ABCB4 gene</article-title><source>Orphanet J Rare Dis</source><year>2007</year><volume>2</volume><fpage>29</fpage><pub-id pub-id-type="doi">10.1186/1750-1172-2-29</pub-id><pub-id pub-id-type="pmid">17562004</pub-id><pub-id pub-id-type="pmcid">PMC1910597</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosmorduc</surname><given-names>O</given-names></name><name name-style="western"><surname>Hermelin</surname><given-names>B</given-names></name><name name-style="western"><surname>Poupon</surname><given-names>R</given-names></name></person-group><article-title>MDR3 gene defect in adults with symptomatic intrahepatic and gallbladder cholesterol cholelithiasis</article-title><source>Gastroenterology</source><year>2001</year><volume>120</volume><issue>6</issue><fpage>1459</fpage><lpage>1467</lpage><pub-id pub-id-type="doi">10.1053/gast.2001.23947</pub-id><pub-id pub-id-type="pmid">11313316</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jacquemin</surname><given-names>E</given-names></name></person-group><article-title>Progressive familial intrahepatic cholestasis</article-title><source>Clin Res Hepatol Gastroenterol</source><year>2012</year><volume>36</volume><issue>Suppl 1</issue><fpage>S26</fpage><lpage>S35</lpage><pub-id pub-id-type="doi">10.1016/S2210-7401(12)70018-9</pub-id><pub-id pub-id-type="pmid">23141890</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RX</given-names></name><name name-style="western"><surname>Han</surname><given-names>J</given-names></name><name name-style="western"><surname>Li</surname><given-names>ZD</given-names></name><name name-style="western"><surname>Sheps</surname><given-names>JA</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>LJ</given-names></name><etal/></person-group><article-title>Comprehensive Bile Acid Profiling of ABCB4-mutated Patients and the Prognostic Role of Taurine-conjugated 3α,6α,7α,12α-Tetrahydroxylated Bile Acid in Cholestasis</article-title><source>J Clin Transl Hepatol</source><year>2024</year><volume>12</volume><issue>2</issue><fpage>151</fpage><lpage>161</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2023.00095</pub-id><pub-id pub-id-type="pmid">38343606</pub-id><pub-id pub-id-type="pmcid">PMC10851069</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>HL</given-names></name><name name-style="western"><surname>Wu</surname><given-names>SH</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>SH</given-names></name><name name-style="western"><surname>Liou</surname><given-names>BY</given-names></name><name name-style="western"><surname>Chen</surname><given-names>HL</given-names></name><name name-style="western"><surname>Chang</surname><given-names>MH</given-names></name></person-group><article-title>Jaundice revisited: recent advances in the diagnosis and treatment of inherited cholestatic liver diseases</article-title><source>J Biomed Sci</source><year>2018</year><volume>25</volume><issue>1</issue><fpage>75</fpage><pub-id pub-id-type="doi">10.1186/s12929-018-0475-8</pub-id><pub-id pub-id-type="pmid">30367658</pub-id><pub-id pub-id-type="pmcid">PMC6203212</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tada</surname><given-names>H</given-names></name><name name-style="western"><surname>Nomura</surname><given-names>A</given-names></name><name name-style="western"><surname>Ogura</surname><given-names>M</given-names></name><name name-style="western"><surname>Ikewaki</surname><given-names>K</given-names></name><name name-style="western"><surname>Ishigaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Inagaki</surname><given-names>K</given-names></name><etal/></person-group><article-title>Diagnosis and Management of Sitosterolemia 2021</article-title><source>J Atheroscler Thromb</source><year>2021</year><volume>28</volume><issue>8</issue><fpage>791</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.5551/jat.RV17052</pub-id><pub-id pub-id-type="pmid">33907061</pub-id><pub-id pub-id-type="pmcid">PMC8326170</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b86"><label>86</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Manautou</surname><given-names>JE</given-names></name><name name-style="western"><surname>Campion</surname><given-names>SN</given-names></name><name name-style="western"><surname>Aleksunes</surname><given-names>LM</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>McQueen</surname><given-names>CA</given-names></name></person-group><article-title>Regulation of Hepatobiliary Transporters during Liver Injury</article-title><source>Comprehensive Toxicology (Second Edition)</source><year>2010</year><publisher-loc>Amsterdam, Netherlands</publisher-loc><publisher-name>Elsevier</publisher-name><fpage>175</fpage><lpage>220</lpage></element-citation></ref><ref id="JCTH-2025-00476-b87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Yu</surname><given-names>XH</given-names></name><name name-style="western"><surname>Ou</surname><given-names>X</given-names></name><name name-style="western"><surname>Ouyang</surname><given-names>XP</given-names></name><name name-style="western"><surname>Tang</surname><given-names>CK</given-names></name></person-group><article-title>Hepatic cholesterol transport and its role in non-alcoholic fatty liver disease and atherosclerosis</article-title><source>Prog Lipid Res</source><year>2021</year><volume>83</volume><fpage>101109</fpage><pub-id pub-id-type="doi">10.1016/j.plipres.2021.101109</pub-id><pub-id pub-id-type="pmid">34097928</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Escolà-Gil</surname><given-names>JC</given-names></name><name name-style="western"><surname>Quesada</surname><given-names>H</given-names></name><name name-style="western"><surname>Julve</surname><given-names>J</given-names></name><name name-style="western"><surname>Martín-Campos</surname><given-names>JM</given-names></name><name name-style="western"><surname>Cedó</surname><given-names>L</given-names></name><name name-style="western"><surname>Blanco-Vaca</surname><given-names>F</given-names></name></person-group><article-title>Sitosterolemia: diagnosis, investigation, and management</article-title><source>Curr Atheroscler Rep</source><year>2014</year><volume>16</volume><issue>7</issue><fpage>424</fpage><pub-id pub-id-type="doi">10.1007/s11883-014-0424-2</pub-id><pub-id pub-id-type="pmid">24821603</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b89"><label>89</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Myrie</surname><given-names>SB</given-names></name><name name-style="western"><surname>Steiner</surname><given-names>RD</given-names></name><name name-style="western"><surname>Mymin</surname><given-names>D</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name><name name-style="western"><surname>Bick</surname><given-names>S</given-names></name><name name-style="western"><surname>Mirzaa</surname><given-names>GM</given-names></name><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>SE</given-names></name><name name-style="western"><surname>Amemiya</surname><given-names>A</given-names></name></person-group><article-title>Sitosterolemia</article-title><source>GeneReviews®</source><year>2025</year><publisher-loc>Seattle (WA)</publisher-loc><publisher-name>University of Washington, Seattle</publisher-name></element-citation></ref><ref id="JCTH-2025-00476-b90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kidambi</surname><given-names>S</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SB</given-names></name></person-group><article-title>Sitosterolaemia: pathophysiology, clinical presentation and laboratory diagnosis</article-title><source>J Clin Pathol</source><year>2008</year><volume>61</volume><issue>5</issue><fpage>588</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1136/jcp.2007.049775</pub-id><pub-id pub-id-type="pmid">18441155</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Miettinen</surname><given-names>TA</given-names></name><name name-style="western"><surname>Klett</surname><given-names>EL</given-names></name><name name-style="western"><surname>Gylling</surname><given-names>H</given-names></name><name name-style="western"><surname>Isoniemi</surname><given-names>H</given-names></name><name name-style="western"><surname>Patel</surname><given-names>SB</given-names></name></person-group><article-title>Liver transplantation in a patient with sitosterolemia and cirrhosis</article-title><source>Gastroenterology</source><year>2006</year><volume>130</volume><issue>2</issue><fpage>542</fpage><lpage>547</lpage><pub-id pub-id-type="doi">10.1053/j.gastro.2005.10.022</pub-id><pub-id pub-id-type="pmid">16472606</pub-id><pub-id pub-id-type="pmcid">PMC1391914</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shani</surname><given-names>M</given-names></name><name name-style="western"><surname>Seligsohn</surname><given-names>U</given-names></name><name name-style="western"><surname>Gilon</surname><given-names>E</given-names></name><name name-style="western"><surname>Sheba</surname><given-names>C</given-names></name><name name-style="western"><surname>Adam</surname><given-names>A</given-names></name></person-group><article-title>Dubin-Johnson syndrome in Israel. I. Clinical, laboratory, and genetic aspects of 101 cases</article-title><source>Q J Med</source><year>1970</year><volume>39</volume><issue>156</issue><fpage>549</fpage><lpage>567</lpage><pub-id pub-id-type="pmid">5532959</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Corpechot</surname><given-names>C</given-names></name><name name-style="western"><surname>Barbu</surname><given-names>V</given-names></name><name name-style="western"><surname>Chazouillères</surname><given-names>O</given-names></name><name name-style="western"><surname>Broué</surname><given-names>P</given-names></name><name name-style="western"><surname>Girard</surname><given-names>M</given-names></name><name name-style="western"><surname>Roquelaure</surname><given-names>B</given-names></name><etal/></person-group><article-title>Genetic contribution of ABCC2 to Dubin-Johnson syndrome and inherited cholestatic disorders</article-title><source>Liver Int</source><year>2020</year><volume>40</volume><issue>1</issue><fpage>163</fpage><lpage>174</lpage><pub-id pub-id-type="doi">10.1111/liv.14260</pub-id><pub-id pub-id-type="pmid">31544333</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>T</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>J</given-names></name><name name-style="western"><surname>Feng</surname><given-names>JY</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sheps</surname><given-names>JA</given-names></name><name name-style="western"><surname>Wang</surname><given-names>RX</given-names></name><etal/></person-group><article-title>Neonatal Dubin-Johnson Syndrome and its Differentiation from Biliary Atresia</article-title><source>J Clin Transl Hepatol</source><year>2023</year><volume>11</volume><issue>1</issue><fpage>163</fpage><lpage>173</lpage><pub-id pub-id-type="doi">10.14218/JCTH.2021.00460</pub-id><pub-id pub-id-type="pmid">36406324</pub-id><pub-id pub-id-type="pmcid">PMC9647112</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Strassburg</surname><given-names>CP</given-names></name></person-group><article-title>Hyperbilirubinemia syndromes (Gilbert-Meulengracht, Crigler-Najjar, Dubin-Johnson, and Rotor syndrome)</article-title><source>Best Pract Res Clin Gastroenterol</source><year>2010</year><volume>24</volume><issue>5</issue><fpage>555</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.bpg.2010.07.007</pub-id><pub-id pub-id-type="pmid">20955959</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b96"><label>96</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Talaga</surname><given-names>ZJ</given-names></name><name name-style="western"><surname>Vaidya</surname><given-names>PN</given-names></name></person-group><article-title>Dubin-Johnson Syndrome</article-title><source>StatPearls</source><year>2025</year><publisher-loc>Treasure Island (FL)</publisher-loc><publisher-name>StatPearls Publishing</publisher-name></element-citation></ref><ref id="JCTH-2025-00476-b97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhao</surname><given-names>X</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>D</given-names></name><name name-style="western"><surname>Xu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Mutation analysis of the ABCC2 gene in Chinese patients with Dubin-Johnson syndrome</article-title><source>Exp Ther Med</source><year>2018</year><volume>16</volume><issue>5</issue><fpage>4201</fpage><lpage>4206</lpage><pub-id pub-id-type="doi">10.3892/etm.2018.6682</pub-id><pub-id pub-id-type="pmid">30344695</pub-id><pub-id pub-id-type="pmcid">PMC6176208</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Memon</surname><given-names>N</given-names></name><name name-style="western"><surname>Weinberger</surname><given-names>BI</given-names></name><name name-style="western"><surname>Hegyi</surname><given-names>T</given-names></name><name name-style="western"><surname>Aleksunes</surname><given-names>LM</given-names></name></person-group><article-title>Inherited disorders of bilirubin clearance</article-title><source>Pediatr Res</source><year>2016</year><volume>79</volume><issue>3</issue><fpage>378</fpage><lpage>386</lpage><pub-id pub-id-type="doi">10.1038/pr.2015.247</pub-id><pub-id pub-id-type="pmid">26595536</pub-id><pub-id pub-id-type="pmcid">PMC4821713</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gotthardt</surname><given-names>D</given-names></name><name name-style="western"><surname>Runz</surname><given-names>H</given-names></name><name name-style="western"><surname>Keitel</surname><given-names>V</given-names></name><name name-style="western"><surname>Fischer</surname><given-names>C</given-names></name><name name-style="western"><surname>Flechtenmacher</surname><given-names>C</given-names></name><name name-style="western"><surname>Wirtenberger</surname><given-names>M</given-names></name><etal/></person-group><article-title>A mutation in the canalicular phospholipid transporter gene, ABCB4, is associated with cholestasis, ductopenia, and cirrhosis in adults</article-title><source>Hepatology</source><year>2008</year><volume>48</volume><issue>4</issue><fpage>1157</fpage><lpage>1166</lpage><pub-id pub-id-type="doi">10.1002/hep.22485</pub-id><pub-id pub-id-type="pmid">18781607</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anzivino</surname><given-names>C</given-names></name><name name-style="western"><surname>Odoardi</surname><given-names>MR</given-names></name><name name-style="western"><surname>Meschiari</surname><given-names>E</given-names></name><name name-style="western"><surname>Baldelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Facchinetti</surname><given-names>F</given-names></name><name name-style="western"><surname>Neri</surname><given-names>I</given-names></name><etal/></person-group><article-title>ABCB4 and ABCB11 mutations in intrahepatic cholestasis of pregnancy in an Italian population</article-title><source>Dig Liver Dis</source><year>2013</year><volume>45</volume><issue>3</issue><fpage>226</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/j.dld.2012.08.011</pub-id><pub-id pub-id-type="pmid">23022423</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Benifla</surname><given-names>JL</given-names></name><name name-style="western"><surname>Dumont</surname><given-names>M</given-names></name><name name-style="western"><surname>Levardon</surname><given-names>M</given-names></name><name name-style="western"><surname>Foucher</surname><given-names>E</given-names></name><name name-style="western"><surname>Cadiot</surname><given-names>G</given-names></name><name name-style="western"><surname>Crenn-Hebert</surname><given-names>C</given-names></name><etal/></person-group><article-title>Effects of micronized natural progesterone on the liver during the third trimester of pregnancy</article-title><source>Contracept Fertil Sex</source><year>1997</year><volume>25</volume><issue>2</issue><fpage>165</fpage><lpage>169</lpage><pub-id pub-id-type="pmid">9116778</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsur</surname><given-names>A</given-names></name><name name-style="western"><surname>Leonard</surname><given-names>SA</given-names></name><name name-style="western"><surname>Kan</surname><given-names>P</given-names></name><name name-style="western"><surname>Datoc</surname><given-names>IA</given-names></name><name name-style="western"><surname>Girsen</surname><given-names>AI</given-names></name><name name-style="western"><surname>Shaw</surname><given-names>GM</given-names></name><etal/></person-group><article-title>Vaginal Progesterone Is Associated with Intrahepatic Cholestasis of Pregnancy</article-title><source>Am J Perinatol</source><year>2023</year><volume>40</volume><issue>11</issue><fpage>1158</fpage><lpage>1162</lpage><pub-id pub-id-type="doi">10.1055/a-2081-2573</pub-id><pub-id pub-id-type="pmid">37100422</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zipori</surname><given-names>Y</given-names></name><name name-style="western"><surname>Bachar</surname><given-names>G</given-names></name><name name-style="western"><surname>Farago</surname><given-names>N</given-names></name><name name-style="western"><surname>Lauterbach</surname><given-names>R</given-names></name><name name-style="western"><surname>Weissman</surname><given-names>A</given-names></name><name name-style="western"><surname>Beloosesky</surname><given-names>R</given-names></name><etal/></person-group><article-title>Vaginal progesterone treatment for the prevention of preterm birth and intrahepatic cholestasis of pregnancy: A case-control study</article-title><source>Eur J Obstet Gynecol Reprod Biol</source><year>2020</year><volume>253</volume><fpage>117</fpage><lpage>120</lpage><pub-id pub-id-type="doi">10.1016/j.ejogrb.2020.08.043</pub-id><pub-id pub-id-type="pmid">32866855</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Glantz</surname><given-names>A</given-names></name><name name-style="western"><surname>Marschall</surname><given-names>HU</given-names></name><name name-style="western"><surname>Lammert</surname><given-names>F</given-names></name><name name-style="western"><surname>Mattsson</surname><given-names>LA</given-names></name></person-group><article-title>Intrahepatic cholestasis of pregnancy: a randomized controlled trial comparing dexamethasone and ursodeoxycholic acid</article-title><source>Hepatology</source><year>2005</year><volume>42</volume><issue>6</issue><fpage>1399</fpage><lpage>1405</lpage><pub-id pub-id-type="doi">10.1002/hep.20952</pub-id><pub-id pub-id-type="pmid">16317669</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bjornsson</surname><given-names>ES</given-names></name><name name-style="western"><surname>Devarbhavi</surname><given-names>HC</given-names></name></person-group><article-title>Drug-induced cholestatic liver diseases</article-title><source>Hepatology</source><year>2025</year><volume>82</volume><issue>4</issue><fpage>996</fpage><lpage>1015</lpage><pub-id pub-id-type="doi">10.1097/HEP.0000000000001052</pub-id><pub-id pub-id-type="pmid">39121063</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vitale</surname><given-names>G</given-names></name><name name-style="western"><surname>Gitto</surname><given-names>S</given-names></name><name name-style="western"><surname>Raimondi</surname><given-names>F</given-names></name><name name-style="western"><surname>Mattiaccio</surname><given-names>A</given-names></name><name name-style="western"><surname>Mantovani</surname><given-names>V</given-names></name><name name-style="western"><surname>Vukotic</surname><given-names>R</given-names></name><etal/></person-group><article-title>Cryptogenic cholestasis in young and adults: ATP8B1, ABCB11, ABCB4, and TJP2 gene variants analysis by high-throughput sequencing</article-title><source>J Gastroenterol</source><year>2018</year><volume>53</volume><issue>8</issue><fpage>945</fpage><lpage>958</lpage><pub-id pub-id-type="doi">10.1007/s00535-017-1423-1</pub-id><pub-id pub-id-type="pmid">29238877</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yeap</surname><given-names>SP</given-names></name><name name-style="western"><surname>Harley</surname><given-names>H</given-names></name><name name-style="western"><surname>Thompson</surname><given-names>R</given-names></name><name name-style="western"><surname>Williamson</surname><given-names>KD</given-names></name><name name-style="western"><surname>Bate</surname><given-names>J</given-names></name><name name-style="western"><surname>Sethna</surname><given-names>F</given-names></name><etal/></person-group><article-title>Biliary transporter gene mutations in severe intrahepatic cholestasis of pregnancy: Diagnostic and management implications</article-title><source>J Gastroenterol Hepatol</source><year>2019</year><volume>34</volume><issue>2</issue><fpage>425</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1111/jgh.14376</pub-id><pub-id pub-id-type="pmid">29992621</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aw</surname><given-names>W</given-names></name><name name-style="western"><surname>Ota</surname><given-names>I</given-names></name><name name-style="western"><surname>Toyoda</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lezhava</surname><given-names>A</given-names></name><name name-style="western"><surname>Sakai</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gomi</surname><given-names>T</given-names></name><etal/></person-group><article-title>Pharmacogenomics of human ABC transporters: detection of clinically important SNPs by SmartAmp2 method</article-title><source>Curr Pharm Biotechnol</source><year>2011</year><volume>12</volume><issue>4</issue><fpage>693</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.2174/138920111795164011</pub-id><pub-id pub-id-type="pmid">21118085</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Karpen</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>BM</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Ichetovkin</surname><given-names>I</given-names></name><name name-style="western"><surname>Rosenthal</surname><given-names>P</given-names></name><name name-style="western"><surname>Sokol</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>Use of a Comprehensive 66-Gene Cholestasis Sequencing Panel in 2171 Cholestatic Infants, Children, and Young Adults</article-title><source>J Pediatr Gastroenterol Nutr</source><year>2021</year><volume>72</volume><issue>5</issue><fpage>654</fpage><lpage>660</lpage><pub-id pub-id-type="doi">10.1097/MPG.0000000000003094</pub-id><pub-id pub-id-type="pmid">33720099</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>CB</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>JS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>PL</given-names></name><name name-style="western"><surname>Wu</surname><given-names>JF</given-names></name><name name-style="western"><surname>Li</surname><given-names>HY</given-names></name><name name-style="western"><surname>Liou</surname><given-names>BY</given-names></name><etal/></person-group><article-title>Combining Panel-Based Next-Generation Sequencing and Exome Sequencing for Genetic Liver Diseases</article-title><source>J Pediatr</source><year>2023</year><volume>258</volume><fpage>113408</fpage><pub-id pub-id-type="doi">10.1016/j.jpeds.2023.113408</pub-id><pub-id pub-id-type="pmid">37019333</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cheema</surname><given-names>HA</given-names></name><name name-style="western"><surname>Waheed</surname><given-names>N</given-names></name><name name-style="western"><surname>Saeed</surname><given-names>A</given-names></name><name name-style="western"><surname>Anjum</surname><given-names>MN</given-names></name><name name-style="western"><surname>Fayyaz</surname><given-names>Z</given-names></name><name name-style="western"><surname>Ijaz</surname><given-names>S</given-names></name></person-group><article-title>The Mutational Landscape Of Genetic Cholestatic Diseases In Pakistani Children</article-title><source>J Pak Med Assoc</source><year>2023</year><volume>73</volume><issue>8</issue><fpage>1610</fpage><lpage>1621</lpage><pub-id pub-id-type="doi">10.47391/JPMA.7069</pub-id><pub-id pub-id-type="pmid">37697751</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shankar</surname><given-names>S</given-names></name><name name-style="western"><surname>Pande</surname><given-names>A</given-names></name><name name-style="western"><surname>Geetha</surname><given-names>TS</given-names></name><name name-style="western"><surname>Raichurkar</surname><given-names>K</given-names></name><name name-style="western"><surname>Sakpal</surname><given-names>M</given-names></name><name name-style="western"><surname>Lochan</surname><given-names>R</given-names></name><etal/></person-group><article-title>A New Variant of an Old Itch: Novel Missense Variant in ABCB4 Presenting with Intractable Pruritus</article-title><source>J Clin Exp Hepatol</source><year>2022</year><volume>12</volume><issue>2</issue><fpage>701</fpage><lpage>704</lpage><pub-id pub-id-type="doi">10.1016/j.jceh.2021.04.010</pub-id><pub-id pub-id-type="pmid">35535055</pub-id><pub-id pub-id-type="pmcid">PMC9077154</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bhatt</surname><given-names>JV</given-names></name><name name-style="western"><surname>Akhoury</surname><given-names>A</given-names></name><name name-style="western"><surname>Vekaria</surname><given-names>VV</given-names></name><name name-style="western"><surname>Parmar</surname><given-names>HR</given-names></name><name name-style="western"><surname>Patel</surname><given-names>DN</given-names></name></person-group><article-title>A Case of Progressive Familial Intrahepatic Cholestasis Type-3</article-title><source>Cureus</source><year>2024</year><volume>16</volume><issue>10</issue><fpage>e72782</fpage><pub-id pub-id-type="doi">10.7759/cureus.72782</pub-id><pub-id pub-id-type="pmid">39618628</pub-id><pub-id pub-id-type="pmcid">PMC11608084</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiao</surname><given-names>Q</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lauschke</surname><given-names>VM</given-names></name></person-group><article-title>Ethnogeographic and inter-individual variability of human ABC transporters</article-title><source>Hum Genet</source><year>2020</year><volume>139</volume><issue>5</issue><fpage>623</fpage><lpage>646</lpage><pub-id pub-id-type="doi">10.1007/s00439-020-02150-6</pub-id><pub-id pub-id-type="pmid">32206879</pub-id><pub-id pub-id-type="pmcid">PMC7170817</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b115"><label>115</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Andersen</surname><given-names>S</given-names></name><name name-style="western"><surname>Okkels</surname><given-names>H</given-names></name><name name-style="western"><surname>Krarup</surname><given-names>H</given-names></name><name name-style="western"><surname>Laurberg</surname><given-names>P</given-names></name></person-group><article-title>Geographical clustering and maintained health in individuals harbouring the mutation for Greenland familial cholestasis: A population-based study</article-title><source>Scand J Gastroenterol</source><year>2006</year><volume>41</volume><issue>4</issue><fpage>445</fpage><lpage>450</lpage><pub-id pub-id-type="doi">10.1080/00365520510024250</pub-id><pub-id pub-id-type="pmid">16635913</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b116"><label>116</label><element-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Bull</surname><given-names>LN</given-names></name><name name-style="western"><surname>Morotti</surname><given-names>R</given-names></name><name name-style="western"><surname>Squires</surname><given-names>JE</given-names></name></person-group><person-group person-group-type="editor"><name name-style="western"><surname>Adam</surname><given-names>MP</given-names></name><name name-style="western"><surname>Bick</surname><given-names>S</given-names></name><name name-style="western"><surname>Mirzaa</surname><given-names>GM</given-names></name><name name-style="western"><surname>Pagon</surname><given-names>RA</given-names></name><name name-style="western"><surname>Wallace</surname><given-names>SE</given-names></name><name name-style="western"><surname>Amemiya</surname><given-names>A</given-names></name></person-group><article-title>ATP8B1 Deficiency</article-title><source>GeneReviews®</source><year>2025</year><publisher-loc>Seattle (WA)</publisher-loc><publisher-name>University of Washington, Seattle</publisher-name></element-citation></ref><ref id="JCTH-2025-00476-b117"><label>117</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Vears</surname><given-names>DF</given-names></name><name name-style="western"><surname>Boyle</surname><given-names>J</given-names></name><name name-style="western"><surname>Jacobs</surname><given-names>C</given-names></name><name name-style="western"><surname>McInerney-Leo</surname><given-names>A</given-names></name><name name-style="western"><surname>Newson</surname><given-names>AJ</given-names></name><collab>Education, Ethics and Social Issues Committee of the Human Genetics Society of Australasia</collab></person-group><article-title>Human Genetics Society of Australasia Position Statement: Genetic Carrier Testing for Recessive Conditions</article-title><source>Twin Res Hum Genet</source><year>2023</year><volume>26</volume><issue>2</issue><fpage>188</fpage><lpage>194</lpage><pub-id pub-id-type="doi">10.1017/thg.2023.15</pub-id><pub-id pub-id-type="pmid">37226803</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b118"><label>118</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>D</given-names></name><name name-style="western"><surname>Yang</surname><given-names>J</given-names></name><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Yu</surname><given-names>H</given-names></name><name name-style="western"><surname>Gong</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>D</given-names></name></person-group><article-title>The regulation of tissue-specific farnesoid X receptor on genes and diseases involved in bile acid homeostasis</article-title><source>Biomed Pharmacother</source><year>2023</year><volume>168</volume><fpage>115606</fpage><pub-id pub-id-type="doi">10.1016/j.biopha.2023.115606</pub-id><pub-id pub-id-type="pmid">37812893</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b119"><label>119</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wagner</surname><given-names>M</given-names></name><name name-style="western"><surname>Fickert</surname><given-names>P</given-names></name><name name-style="western"><surname>Zollner</surname><given-names>G</given-names></name><name name-style="western"><surname>Fuchsbichler</surname><given-names>A</given-names></name><name name-style="western"><surname>Silbert</surname><given-names>D</given-names></name><name name-style="western"><surname>Tsybrovskyy</surname><given-names>O</given-names></name><etal/></person-group><article-title>Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice</article-title><source>Gastroenterology</source><year>2003</year><volume>125</volume><issue>3</issue><fpage>825</fpage><lpage>838</lpage><pub-id pub-id-type="doi">10.1016/s0016-5085(03)01068-0</pub-id><pub-id pub-id-type="pmid">12949728</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b120"><label>120</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ogata</surname><given-names>M</given-names></name><name name-style="western"><surname>Tsujita</surname><given-names>M</given-names></name><name name-style="western"><surname>Hossain</surname><given-names>MA</given-names></name><name name-style="western"><surname>Akita</surname><given-names>N</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>FJ</given-names></name><name name-style="western"><surname>Staels</surname><given-names>B</given-names></name><etal/></person-group><article-title>On the mechanism for PPAR agonists to enhance ABCA1 gene expression</article-title><source>Atherosclerosis</source><year>2009</year><volume>205</volume><issue>2</issue><fpage>413</fpage><lpage>419</lpage><pub-id pub-id-type="doi">10.1016/j.atherosclerosis.2009.01.008</pub-id><pub-id pub-id-type="pmid">19201410</pub-id><pub-id pub-id-type="pmcid">PMC2790138</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b121"><label>121</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>B</given-names></name><name name-style="western"><surname>Shen</surname><given-names>X</given-names></name><name name-style="western"><surname>Chen</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>F</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Z</given-names></name><etal/></person-group><article-title>AAV-mediated gene therapy restores natural fertility and improves physical function in the Lhcgr-deficient mouse model of Leydig cell failure</article-title><source>Cell Prolif</source><year>2024</year><volume>57</volume><issue>9</issue><fpage>e13680</fpage><pub-id pub-id-type="doi">10.1111/cpr.13680</pub-id><pub-id pub-id-type="pmid">38817099</pub-id><pub-id pub-id-type="pmcid">PMC11503244</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b122"><label>122</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sgodda</surname><given-names>M</given-names></name><name name-style="western"><surname>Gebel</surname><given-names>E</given-names></name><name name-style="western"><surname>Dignas</surname><given-names>L</given-names></name><name name-style="western"><surname>Alfken</surname><given-names>S</given-names></name><name name-style="western"><surname>Eggenschwiler</surname><given-names>R</given-names></name><name name-style="western"><surname>Stalke</surname><given-names>A</given-names></name><etal/></person-group><article-title>iPSC-based hepatic organoids reveal a heterozygous MYO5B variant as driver of intrahepatic cholestasis</article-title><source>Hepatol Commun</source><year>2025</year><volume>9</volume><issue>10</issue><fpage>e0812</fpage><pub-id pub-id-type="doi">10.1097/HC9.0000000000000812</pub-id><pub-id pub-id-type="pmid">41021273</pub-id><pub-id pub-id-type="pmcid">PMC12483071</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b123"><label>123</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Aronson</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Bakker</surname><given-names>RS</given-names></name><name name-style="western"><surname>Shi</surname><given-names>X</given-names></name><name name-style="western"><surname>Duijst</surname><given-names>S</given-names></name><name name-style="western"><surname>Ten Bloemendaal</surname><given-names>L</given-names></name><name name-style="western"><surname>de Waart</surname><given-names>DR</given-names></name><etal/></person-group><article-title>Liver-directed gene therapy results in long-term correction of progressive familial intrahepatic cholestasis type 3 in mice</article-title><source>J Hepatol</source><year>2019</year><volume>71</volume><issue>1</issue><fpage>153</fpage><lpage>162</lpage><pub-id pub-id-type="doi">10.1016/j.jhep.2019.03.021</pub-id><pub-id pub-id-type="pmid">30935993</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b124"><label>124</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Li</surname><given-names>CZ</given-names></name><name name-style="western"><surname>Ogawa</surname><given-names>H</given-names></name><name name-style="western"><surname>Ng</surname><given-names>SS</given-names></name><name name-style="western"><surname>Chen</surname><given-names>X</given-names></name><name name-style="western"><surname>Kishimoto</surname><given-names>E</given-names></name><name name-style="western"><surname>Sakabe</surname><given-names>K</given-names></name><etal/></person-group><article-title>Human iPSC-derived hepatocyte system models cholestasis with tight junction protein 2 deficiency</article-title><source>JHEP Rep</source><year>2022</year><volume>4</volume><issue>4</issue><fpage>100446</fpage><pub-id pub-id-type="doi">10.1016/j.jhepr.2022.100446</pub-id><pub-id pub-id-type="pmid">35284810</pub-id><pub-id pub-id-type="pmcid">PMC8904612</pub-id></element-citation></ref><ref id="JCTH-2025-00476-b125"><label>125</label><element-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Imagawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Takayama</surname><given-names>K</given-names></name><name name-style="western"><surname>Isoyama</surname><given-names>S</given-names></name><name name-style="western"><surname>Tanikawa</surname><given-names>K</given-names></name><name name-style="western"><surname>Shinkai</surname><given-names>M</given-names></name><name name-style="western"><surname>Harada</surname><given-names>K</given-names></name><etal/></person-group><article-title>Generation of a bile salt export pump deficiency model using patient-specific induced pluripotent stem cell-derived hepatocyte-like cells</article-title><source>Sci Rep</source><year>2017</year><volume>7</volume><fpage>41806</fpage><pub-id pub-id-type="doi">10.1038/srep41806</pub-id><pub-id pub-id-type="pmid">28150711</pub-id><pub-id pub-id-type="pmcid">PMC5288783</pub-id></element-citation></ref></ref-list></back></article>